

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 222 835 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **28.09.94** (51) Int. Cl.⁵: **A61K 39/385, C07K 17/00, C12N 1/20, C12N 15/00**
- (21) Application number: **86903134.4**
- (22) Date of filing: **14.05.86**
- (96) International application number:
PCT/AU86/00135
- (97) International publication number:
WO 86/06635 (20.11.86 86/25)

(54) ORAL VACCINES.

- | | | | | | | | | | | | | | | | | | | | | | | | |
|---|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|---------------|---------------|---------------|---------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|--|--|
| <p>(30) Priority: 15.05.85 AU 566/85
25.10.85 AU 3104/85</p> <p>(43) Date of publication of application:
27.05.87 Bulletin 87/22</p> <p>(45) Publication of the grant of the patent:
28.09.94 Bulletin 94/39</p> <p>(64) Designated Contracting States:
BE CH DE FR GB IT LI NL SE</p> <p>(56) References cited:</p> <table border="0"> <tr> <td>EP-A- 0 020 147</td> <td>EP-A- 0 049 945</td> </tr> <tr> <td>EP-A- 0 060 129</td> <td>EP-A- 0 116 201</td> </tr> <tr> <td>EP-A- 0 177 343</td> <td>EP-A- 0 178 867</td> </tr> <tr> <td>WO-A-83/02393</td> <td>WO-A-83/03971</td> </tr> <tr> <td>WO-A-85/04654</td> <td>WO-A-85/05037</td> </tr> <tr> <td>AU-A- 1 199 083</td> <td>AU-A- 3 449 784</td> </tr> <tr> <td>AU-A- 4 458 885</td> <td>AU-B- 1 470 576</td> </tr> <tr> <td>FR-A- 2 306 684</td> <td>GB-A- 2 071 671</td> </tr> <tr> <td>GB-A- 2 094 314</td> <td>GB-B- 1 529 871</td> </tr> <tr> <td>US-A- 4 372 883</td> <td>US-A- 4 496 538</td> </tr> <tr> <td>US-A- 4 556 555</td> <td></td> </tr> </table> | EP-A- 0 020 147 | EP-A- 0 049 945 | EP-A- 0 060 129 | EP-A- 0 116 201 | EP-A- 0 177 343 | EP-A- 0 178 867 | WO-A-83/02393 | WO-A-83/03971 | WO-A-85/04654 | WO-A-85/05037 | AU-A- 1 199 083 | AU-A- 3 449 784 | AU-A- 4 458 885 | AU-B- 1 470 576 | FR-A- 2 306 684 | GB-A- 2 071 671 | GB-A- 2 094 314 | GB-B- 1 529 871 | US-A- 4 372 883 | US-A- 4 496 538 | US-A- 4 556 555 | | <p>(73) Proprietor: BIOTECHNOLOGY AUSTRALIA PTY. LTD.
28 Barcoo Street
East Roseville, NSW 2069 (AU)</p> <p>(72) Inventor: RUSSELL-JONES, Gregory, John
101/2 Artarmon Road
Willoughby, NSW 2068 (AU)
Inventor: DE AIZPURUA, Henry, James
9 Douglas Street
Bexley, NSW 2207 (AU)
Inventor: HOWE, Peter
6 Mundon Place
West Pennant Hills, NSW 2120 (AU)
Inventor: RAND, Keith, Norman
10A Ferncourt Avenue
Chatswood, NSW 2067 (AU)</p> <p>(74) Representative: Adkins, Michael et al
Withers & Rogers
4 Dyer's Buildings
Holborn
London EC1N 2JT (GB)</p> |
| EP-A- 0 020 147 | EP-A- 0 049 945 | | | | | | | | | | | | | | | | | | | | | | |
| EP-A- 0 060 129 | EP-A- 0 116 201 | | | | | | | | | | | | | | | | | | | | | | |
| EP-A- 0 177 343 | EP-A- 0 178 867 | | | | | | | | | | | | | | | | | | | | | | |
| WO-A-83/02393 | WO-A-83/03971 | | | | | | | | | | | | | | | | | | | | | | |
| WO-A-85/04654 | WO-A-85/05037 | | | | | | | | | | | | | | | | | | | | | | |
| AU-A- 1 199 083 | AU-A- 3 449 784 | | | | | | | | | | | | | | | | | | | | | | |
| AU-A- 4 458 885 | AU-B- 1 470 576 | | | | | | | | | | | | | | | | | | | | | | |
| FR-A- 2 306 684 | GB-A- 2 071 671 | | | | | | | | | | | | | | | | | | | | | | |
| GB-A- 2 094 314 | GB-B- 1 529 871 | | | | | | | | | | | | | | | | | | | | | | |
| US-A- 4 372 883 | US-A- 4 496 538 | | | | | | | | | | | | | | | | | | | | | | |
| US-A- 4 556 555 | | | | | | | | | | | | | | | | | | | | | | | |

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Journal of Immunological Methods, Vol. 48
Issued 1982 (Amsterdam, Netherlands)
P.R.Lambden and J.E. Heckels, pages
233-240

Progress in Allergy, vo. 33, Issued 1983 (Basel, Switzerland) Schoolnik et al, "A Pilus, Peptide Vaccine for the Prevention of Gonorrhea", see pages 314-331

M. Susman, "The Virulence of Escherichia coli" 1985, Academic Press, see pages 82-37, 111-119

Description

The present invention relates to the specific stimulation of serum and secretory antibodies through mucosal presentation of antigens.

BACKGROUND ART

A number of infections in mammals have sufficient deleterious effects on the mammal to warrant vaccination against the particular antigen responsible for the infection. Therefore, vaccination programmes are instituted whereby the mammal is antigenically challenged with an antigen so that an immune response is elicited to confer immunity to the mammal.

Administration of the antigen to the mammal may be through a number of routes including injection intramuscularly (i.m.), subcutaneously (s.c.), or through oral administration (per os). I.m. or s.c. injection of antigen suffers from the disadvantages that relatively specialized skills are required, it is difficult to undertake on a large scale, it is expensive, and a number of side reactions can occur to either the immunizing antigen or to the emulsifying reagent in which it is presented. Oral administration of vaccines is by contrast relatively problem free except insofar as oral feeding of a number of antigens requires relatively large quantities of antigen as the amount of material that is actually absorbed and capable of stimulating an effective immune response is usually low. Thus the amount of antigen required for oral immunization generally far exceeds that required for systemic induction of immunity. There is also one major disadvantage to the oral presentation of the large quantities of antigen required to produce an antibody response and that is that feeding of these large quantities of antigen often leads to the induction of systemic tolerance (Tomasi, 1980; Mowat, 1985; Mowat and Parrot, 1983; Ngan & Kind, 1978; Hanson et al, 1979; Richman et al. 1978; Rothberg et al., 1973).

Evidence to date suggests that in general the mechanism by which antigen is taken up by the small intestine, following oral feeding, is primarily via non-specific sampling of the contents of the gut lumen by "M" cells which overlie the Peyer's Patches and other lymphoid clusters of the GALT (gut-associated-lymphoid tissue) (Bland and Britton, 1984). The subsequent sensitization of local lymphocyte populations leads to the generation of local IgA immune responses plus the sensitization of IgG suppressor cells with concomitant suppression of serum IgG responses (Tomasi, 1980; Mowat, 1985; Mowat and Parrot, 1983; Ngan & Kind, 1978; Hanson et al, 1979; Richman et al, 1978; Rothberg et al, 1973).

It is therefore apparent that the site of antigen uptake, whether it be through the Peyer's Patches or the villous epithelium, and quite probably the amount of antigen administered, dictates the type of immune response generated by orally administered antigen. The question arises then as to whether there are any other antigens apart from cholera toxin which exhibit the ability to specifically prime the mucosal immune system upon oral challenge and/or to stimulate the humoral immune response in a dose dependant manner without inducing systemic tolerance and without the need for excessive doses of antigen.

With this view in mind we decided to investigate the possible potential of certain adhesive molecules, which have been implicated in the initial attachment of a number of intestinal pathogens, to stimulate the immune response when orally administered. These surface antigens which confer adhesive properties to a number of strains of enterotoxigenic E. coli (ETEC) have been identified as nonflagellar, filamentous proteinaceous appendages, or pili (Gaastra & de Graaf, 1982). Examples include the CFA I and CFA II antigens of human ETEC strains and the K88, K99, F41 and 987P pili of animal ETEC strains (Gibbons et al, 1975; Evans & Evans, 1978; Levine et al., 1980; Morgan et al., 1978; de Graaf & Roorda, 1982). In addition, we have examined the ability of a number of other proteins which have no apparent role in colonization to prime the immune system upon oral feeding. These antigens included a number of lectins a serotypic antigen of S.typhimurium (the type "i" flagella), inactivated flu virus and S.typhimurium endotoxin (LPS). Oral priming was compared to the response generated to wholly intramuscular challenge (i.m.).

Thus, the aim of these studies was to provide a method whereby the uptake of an immunogen or antigen by the gastrointestinal tract mucosa is improved to the extent that it is possible to elicit serum and secretory antibodies by oral feeding of low doses of the immunogen without the induction of oral tolerance.

Accordingly the invention describes a group of molecules (mucosal immunogens) which when fed lead to the production of serum antibodies to these proteins at comparable levels to those obtained by intramuscular injection of these molecules. Furthermore when larger quantities of these antigens are fed there is a concomitant stimulation of the production of mucosal antibodies to the immunizing molecules.

In a further aspect of this invention a process is described whereby the antibody response generated to the orally fed molecules can be augmented) or changed by the co-feeding of a number of dietary molecules.

In another aspect of this invention a process is described whereby a hapten or protein can be coupled to a mucosal immunogen and the complex of which, when fed, results in the production of antibodies to the hapten or coupled protein.

5

10

15

20

25

ABBREVIATIONS		
1.	Ab	Antibody
2.	BSA	bovine serum albumin
3.	ConA	Concanavalin A
4.	DNP	dinitrophenyl
5.	ELISA	Enzyme linked immunosorbent assay
6.	ETEC	enterotoxigenic <i>E. coli</i>
7.	GALT	gut associated lymphoid tissue
8.	HA	hydroxy apatite
9.	im	intra muscular
10.	LHRH	luteinizing hormone releasing hormone.
11.	LPS	lipopolysaccharide
12.	LT-B	heat labile toxin of enterotoxigenic <i>E. coli</i> .
13.	O/N	overnight
14.	per oo	oral administration
15.	ps	polysaccharide
16.	RT	room temperature
17.	sc	subcutaneous
18.	SDS-PAGE	SDS - polyacrylamide gel electrophoresis
19.	TCA	trichloroacetic acid.

DISCLOSURE OF INVENTION

30

In a first form the invention provides a complex comprising: an immunogen suitable for vaccination purposes;

35

linked to a carrier molecule which is capable of specifically interacting with the mucosal epithelium of a vertebrate host; wherein both the immunological activity of the immunogen and the capacity of the carrier molecule to specifically interact with the mucosal epithelium of the vertebrate host is substantially maintained, and said complex is capable of eliciting a systemic, cellular and/or mucosal immune response in the vertebrate host.

40

Preferred immunogens according to the invention include: an antigen or hapten or all, part, analogues, homologues, derivatives or combinations of a hormone or therapeutic agent. These immunogens include hormones such as LHRH (luteinising hormone releasing hormone) FSH, HGH and Inhibin; allergens such as grass pollens (for instance barley and couch), weed pollens (eg. clover, dock), tree pollens (eg. ash, cyprus), plant pollens (eg. broom), epithelia (eg. cat hair, dog hair, pig hair) and house dust, wheat chaff and Kapok; immunogens for vaccines against agents such as influenza, measles, Rubella, smallpox, yellow fever, diphtheria, tetanus, cholera, plague, typhus, BCG, *haemophilus influenzae*, *Neisseria catarrhalis*, *Klebsiella pneumoniae*, *pneumococci* and *streptococci* especially *S. mutans*; and pili including pili derived from *E. coli*, *N. gonorrhoeae*, *N. meningitis*, *N. catarrhalis*, *Yersinia* spp, *Pseudomonas aeruginosa*, *Pseudomonas* spp, *Moraxella bovis*, *Bacteroides nodosus*, *Staphylococci* spp, *Streptococci* spp and *Bordetella* spp.

45

50

55

Preferred carrier molecules include bacterial adhesins such as 987P, K99, CFAI, CFAll, K88 or F41; viral haemagglutinins such as from influenza, measles, Rubella, smallpox or yellow fever viruses; toxins or binding subunits thereof such as LTb ricin, abrin, diphtheria toxin, modecin, tatanus toxin and others of similar structures; and lectins whether from plant or other origin. Lectins include for example concanavalin A, Pokeweed mitogen or lectins from *Lens culinaris*, *Helix pomatia*, *Glycine max*, *Arachis hypogaea*, or *Ulex europeus* or Abrin, Asparagus pea, Broad bean, Camel's foot tree, Castor bean, Fava bean, Green marine algae, Hairy vetch, Horse gram, Horse shoe crab, Jack bean, Japanese wisteria, Jequirity, Scotch laburnum, Lima bean, Limulin, Lotus, European mistletoe, Mung bean, Osage orange, Pagoda tree, Garden pea, Potato, Red kidney bean, Red marine algae, Siberian pea tree, edible snail, garden snail, Spindle tree, Sweet pea, Tomato, wheat germ or winged pea.

In a preferred embodiment of the invention there is provided a complex which comprises luteinising hormone releasing hormone and LTB.

In another form the present invention provides a process for the production of a complex as described above which process comprises;

- 5 (a) reacting the immunogen with the carrier molecule to form said complex;
- (b) chemically modifying the immunogen to provide at least one functional group capable of forming a chemical linkage, and reacting the immunogen and carrier molecule to form said complex; or
- (c) chemically modifying the carrier molecule to provide at least one functional group capable of forming a chemical linkage, and reacting the immunogen and carrier molecule to form said complex;
- 10 (d) chemically modifying the immunogen and the carrier molecule to provide functional groups capable of forming a chemical linkage, and reacting the immunogen and carrier molecule to form said complex;
- (e) reacting the immunogen with at least one linking agent, and reacting the immunogen and the carrier molecule to form said complex;
- (f) reacting the carrier molecule with at least one linking agent and reacting the immunogen and the carrier molecule to form said complex;
- 15 (g) reacting the immunogen and the carrier molecule with at least one linking agent, and reacting the immunogen and the carrier molecule to form said complex; or
- (h) a combination of any of the preceding process steps.

- In another form the invention provides a process which comprises
- 20 providing a recombinant DNA molecule comprising a first DNA sequence which on expression codes for the amino acid sequence of the immunogen, a second DNA sequence which on expression codes for the amino acid sequence of the carrier molecule, and vector DNA;
 - transforming a host with said recombinant DNA molecule so that said host is capable of expressing a hybrid, proteinaceous product which comprises said complex; culturing said host to obtain said expression;
 - 25 and collecting said hybrid proteinaceous product.

Alternatively the invention provides a process for the production of a complex which process comprises

- (a) chemically synthesising the immunogen and/or the carrier molecule, and forming the complex by chemical reaction;

- or
- 30 (b) synthesising a hybrid peptide comprising amino acid sequences of the immunogen and the carrier molecule. Preferably the peptide is prepared by solid phase, enzymatic or manual peptide synthesis.

In a preferred form of the invention the synthesised immunogen or carrier molecule whilst bound to the resin of the solid phase peptide synthesiser is coupled to the carrier molecule or immunogen respectively.

- In another form of the present invention there is provided a transformant host transformed with a recombinant DNA molecule comprising a first DNA sequence which on expression codes for the amino acid sequences of all, part, an analogue, homologue, derivative or combination thereof, of the immunogen, a second DNA sequence which on expression codes for the amino acid sequence of all, part, an analogue, homologue, derivative or combination thereof of the carrier molecule, and vector DNA.

- In a preferred form of the invention the transformant host is a Gram negative or Gram positive bacterium, a yeast, Fungus or a higher eukaryotic cell. In one preferred form of the invention, said host is E.coli.

- In a further form the invention provides a recombinant DNA molecule comprising a first DNA sequence which on expression codes for the amino acid sequence of the immunogen, a second DNA sequence which on expression codes for the amino acid sequence of the carrier molecule, and vector DNA. In a preferred embodiment of this form of the invention, the vector DNA is plasmid DNA but alternative vectors are envisaged within the scope of the present invention and these include viruses, bacteriophages and cosmids. In one preferred form of the invention there is provided plasmid pBTAK66 which when a host cell is transformed with said plasmid will yield a proteinaceous product which includes a polypeptide falling within the scope of the present invention.

- In a further form of the invention there is provided a polynucleotide sequence which comprises a first hybrid polynucleotide sequence which acts as a coding sequence for a fusion product comprising an amino acid sequence of an immunogen fused to an amino acid sequence of a carrier molecule, a polynucleotide sequence sufficiently related to said first hybrid polynucleotide sequence so as to hybridize to said first hybrid polynucleotide sequence, a polynucleotide sequence related by mutation, including single or multiple base substitutions, deletions, insertions and inversions, to said first hybrid polynucleotide sequence or hybridizing sequence or a polynucleotide sequence which on expression codes for a polypeptide which displays similar biological or immunological activity to said fusion product.

Preferably the polynucleotide sequence is one wherein the first hybrid polynucleotide sequence acts as a coding sequence for the amino acid sequence of all, part, an analogue, homologue, derivative or combination thereof of LHRH fused to the amino acid sequence of a carrier molecule, more preferably LTB.

In a further form of the invention there is provided a medicament which comprises a complex according to the invention together with a pharmaceutically acceptable carrier or diluent. Examples of pharmaceutically acceptable carriers and diluents include typical carriers and diluents such as tablets, aqueous solutions, sodium bicarbonate solutions and similar diluents which neutralise stomach acid or have similar buffering capacity, glycols, oils, oil-in-water or water-in-oil emulsions, and include medicaments in the form of emulsions, gels, pastes and viscous colloidal dispersions. The medicament may be presented in capsule, tablet, slow release or elixir form or as a gel or paste or may be presented as a nasal spray and in this form may be in the presence of an aerosol. Furthermore, the medicament may be provided as a live stock feed or as food suitable for human consumption.

The present inventors have also found that co-administration of certain dietary molecules with a complex of the present invention can selectively modulate the magnitude and/or type of the immune response to the immunogen of the complex.

Accordingly the present invention further provides a medicament which comprises the complex of the present invention together with a dietary molecule which dietary molecule can selectively modulate the magnitude and/or type of the immune response to the immunogen of the complex.

The dietary molecule envisaged by the present invention include basic, neutral and acidic amino acids, such as arginine, histidine, lysine, alanine, cysteine, cystine, glycine, isoleucine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, aspartic acid, glutamic acid; water soluble and insoluble vitamins, such as thiamine, riboflavin, pyridoxal cyanocobalamin (V.B₁₂) ascorbic acid (V.C), Vit D₂, etc - Ergosterol, Vit.E, Vit.A, Vit K etc; sugars including monosaccharides e.g. galactose, mannose, mannitol, sorbitol, glucose, xylose, Allose, altrose, arabinose, digitoxose, erythrose, fructose, lyxose, muramic acid, mannose, pyruvic acid, ribose, tagatose, talose and the amidated and N acetylated derivatives thereof; oligosaccharides e.g. lactose, maltose, melibiose, sucrose, cellubiose, N,N diacetyl chitobiose, gentobiose, isomaltose, lactobionic acid, trehalose, turanose; and dietary minerals and co-factors such as manganese, magnesium, zinc, calcium and iron.

The invention also provides a method of presenting a complex of the present invention which method comprises the mucosal administration of a complex of the present invention together with a dietary molecule capable of modulating the magnitude and/or type of immune response of the immunogen.

The invention also provides the oral administration of the medicaments of the invention, in order to elicit a response to the active molecule in the host. Such a response, in the case where the active molecule is an antigen or hapten may be a systemic and/or a mucosal immune response. In the case where the active molecule is LHRH or a derivative, analogue, homologue, part or combination thereof, of LHRH, the response will be inhibition of gonadal function in the host. Where the oral medicament incorporates a dietary molecule according to the invention, the invention provides a method for enhancing the host's response to the active molecule which comprises administering such an oral medicament to the host.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the N-terminal amino acid sequence of the 987P pilin subunit, in comparison with the N-terminal amino acid sequence of other pilin proteins.

MODES FOR CARRYING OUT THE INVENTION

Materials

Lectins were purchased from Sigma Chemical Co. Inactivated flu vaccine was purchased from the Commonwealth Serum Labs. (Australia). Sugars and vitamins were obtained from the following sources:- Lactose (AR grade) - Ajax Chemicals, Sydney, Australia; Fructose D(-), Mannose D(+), Sorbitol and Xylose D(+) (all AR grade)- B.D.H. Chemicals Ltd. Poole, England; Melibiose D(+) - Sigma Chemical Co., St. Louis, Miss.; Retinal (Vit A. aldehyde)- Fluka AG, Chemicals, Fabrik Buchs, Switzerland; Thiamine - HCl (Vit B1), Riboflavin (Vit B2), Pyridoxal (Vit B6), Cyanocobalamin (Vit B12), L-ascorbic acid (Vit C), Ergosterol (Pro Vit D) and dl-a-tocopherol (Vit E)- Sigma Chemical Co., St. Louis, Miss.

Bacterial Strains and Media

The *E. coli* K99, 987P and LTB strains used in these experiments are listed in Table 1, and were the generous gifts of Dr. Susan Clark, (Molecular Biology Laboratory Biotechnology Australia). Cultures were grown at 37C (unless otherwise specified) with shaking in Luria broth (LB) with or without 1mM isopropylthio-n-D-galactopyranoside (IPTG) as indicated (Table 1). *Salmonella typhimurium* was grown at 37C with shaking in LB plus 0.2% glycerol.

TABLE 1

<u>Strain</u>	<u>Genetic Marker</u>	<u>Strain Origin</u>	<u>Phenotype</u>
BTA 595	p BTA 193	RB 791	LTB +
BTA 604	p BTA 201	MC 1061	987P
BTA 262	p BTA 106	ED 8654	K99

+ Included \sim 1mM IPTG

PURIFICATION OF ANTIGENSPili preparation

E. coli expressing the cloned pili, as detected using radiolabelled antiserum were harvested during logarithmic phase of growth. Cultures were heated at 60C for 30 minutes, after which the organisms were pelleted by centrifugation (3,000 x g, 30 min 4C). The supernatant was examined for pili content by 12.5% SDS-PAGE using a modification of the method of Laemmli (Laemmli, 1970; Salit et al., 1980).

K99 purification:- The culture supernatant was adjusted to pH 9.7 with (10N NaOH and stirred at room temperature (R.T.) for 10 minutes. The resultant precipitate containing pili was recovered by centrifugation (3,000 x g, 30 min 4C) and resuspended in 100ml distilled H₂O (dH₂O) pH 7.2. This procedure was repeated twice.

987P Purification:- Procedures used were as detailed above except that pili precipitation was achieved by adjusting the pH to 3.9 with glacial acetic acid.

Hydroxyapatite chromatography

Hydroxyapatite (HA) (DNA grade Bio-Gel HTP, Bio-Rad) was gently swollen in an excess of dH₂O and after a brief period (< 2 min.) fines were decanted gently. Fresh dH₂O was added and used to gently resuspend the gel after which fines were decanted again. This procedure was repeated several times. A column (30 x 5 cm) was filled with a slurry of approximately 30% HA and allowed to settle by gravity. Tight packing was then achieved by passing dH₂O through the column at a flow rate of 16ml/hr until the gel bed surface was stationary. Samples (100 ml) of either K99 or 987P were applied at flow rates not exceeding 30ml per hour. The column was then washed with dH₂O until no protein was detected in the flow through as detected at 280 nm. Pili were eluted at a flow rate of 30ml/hr using a linear gradient of 15 to 250 mM sodium phosphate pH 7.5. Fractions were collected and examined by SDS-PAGE. The pili peak was recovered and pooled.

Ion-exchange Chromatography

Pooled fractions of K99 and 987P pili (from the HA chromatography) were reprecipitated with NaOH (pH 9.7) or glacial acetic acid (pH 3.9) respectively. After centrifugation (3,000 x g, 10 min), the pellets containing pili were resuspended in 50 mM Citrate buffer, pH 5.5 (K99) and 50 mM Tris.HCl pH 8.5 (987P)

prior to loading on the ion-exchange columns equilibrated with the same buffers. K99 and 987P were loaded onto CM and DEAE columns respectively at a flow rate of 100ml/hr, washed with 2 volumes of loading buffer and the pili eluted using a linear gradient from 10 mM to 0.5 M NaCl in the equilibration buffers. Fractions were examined by SDS-PAGE for protein content and LPS contamination, according to the method of Tsai and Frasch (1982).

LTB Purification

Three litres of LTB supernatant was diluted to 6l with dH₂O. The pH was adjusted to 6.5 with glacial acetic acid and loaded onto a 5 x 30 cm column of fastflow CM-Sepharose equilibrated with 10 mM phosphate buffer pH 6.5 at a flow rate of 1.2 l/hr. The column was then washed with 400 mls of 10 mM phosphate buffer pH 6.5 and bound protein eluted with a linear gradient of 10-500 mM NaCl in 10 mM phosphate pH 6.5. Fractions were collected and analysed by SDS-PAGE, the LTB peak was pooled.

Flagellae Isolation

Late log phase cultures of bacteria were pelleted by centrifugation (3,000 x g for 15 mins. at 4°C). The cells were resuspended in saline and heated at 60°C for 30 minutes, followed by centrifugation (3000 x g, 10 min 4°C). The supernatant was precipitated by adding a solution of 100% TCA (w/v) to give a final concentration of 10% (w/v) and spun for 10 min at 1,500 x g 4°C. The pellet was resuspended in a small volume of 1 M Tris pH 8.8 and sonicated until in solution. Ethanol was added to a final concentration of 80% (v/v) and the flagellae spun down at 2,000 x g, 10 min at 4°C. The pellet was resuspended in acetone, sonicated into suspension and reprecipitated by centrifugation (5,000 x g). Finally the pellet was brought into solution by boiling in 10% SDS and 50 mM EDTA in 10 mM Tris. HCl pH 8.0. prior to Sephacryl S-200 chromatography.

Flagellae purification

After boiling for 15 min the flagellae were clarified by centrifugation for 5 min. in a Beckman benchtop microfuge to remove non-solubilized material. The supernatant was applied to a 2.5 x 80 cm column of Sephacryl - S200 (Pharmacia, Fine Chemicals) equilibrated with 20 mM Tris pH 8.8, 0.1% SDS and 10 mM EDTA and eluted using the same buffer. Fractions were collected and analysed by SDS-PAGE. Finally the flagellae peak was pooled and precipitated with 10% (final conc.) TCA followed by centrifugation, ethanol and acetone washes as described previously. The final pellet was resuspended in dH₂O.

Lipopolysaccharide (LPS) Purification

Overnight cultures of *S. typhimurium* were extracted (30 min R.Temp) with 0.5 M CaCl₂ in 20% ethanol (v/v) containing 100 mM citrate pH 3.0 and 5% Zwittergent 3.12 (w/v) (Calbiochem.). Bacteria were pelleted by centrifugation (3,000 x g, 10 min at 4°C) and the pellet resuspended in 50 mM EDTA pH 8.0. The suspension was stirred vigorously for 30 min at R.T. After removal of the bacteria by centrifugation ethanol was added to the supernatant to a final concentration of 75%. Protein material was pelleted and the supernatant adjusted to 90% ethanol. The precipitate which formed was pelleted and washed with acetone, reprecipitated and finally resuspended in dH₂O. The preparation was assayed for sugar content using the Anthrone reagent (Herbert et al, 1985) and checked for the presence of contaminating proteins using SDS-PAGE. Commercial *E. coli* LPS (Sigma Chemical Co.) was used as a standard in both assays. Gels were stained for LPS using a silver stain according to the method of Tsai and Frasch (1982).

Preparation of Polysaccharide (PS)

Lipid A was cleaved from the *S. typhimurium* LPS preparation by incubating the LPS with 1 M glacial acetic acid and heating at 100°C for 2-5 hrs. Lipid A was then removed by centrifugation at 3,000 x g for 10 mins at 4°C.

Description of Purified Antigens

SDS-PAGE analysis of purified K99 and 987P pili preparations revealed the presence of a single band migrating at 17,500 and 20,000 mol. wt. (respectively) under reducing conditions (Fig. 1). This agrees with

the published data of Isaacson and others (Isaacson & Richter, 1981; Morris et al. 1980; de Graaf et al, 1981; Fusco et al, 1978). The ease of precipitation of these proteins at pH 9.7 and 3.9 (for K99 and 987P, respectively suggests that the pI of these two proteins to be around thes ranged (see:- Isaacson & Richter, 1981; de Graaf et al, 1981). Silver staining of these preparations showed them to contain little (< 1 µg / 100 µg protein) or no contamination with LPS.

Determination of the 987P Amino Terminal Sequence

Amino terminal micro-sequencing was perfored for us by Biotechnology Research Enterprises S.A. Pty. Ltd. Adelaide, South Australia. A 100 nmole sample of 987P purified as described above was assayed. The amino terminal sequence of 987P is compared with the published sequence of K99 and reveals no homology between these two molecules (Fig. 1) (Gaastra and de Graaf, 1982).

Purified LTB, and *S.typhimurium* flagellae were also found to be free of contaminating LPS and to travel as monomers of apparent molecular weights of 12,500 and 52,000 respectively when examined by SDS-PAGE under reducing conditions.

Silver stained SDS-PAGE gels of purified LPS revealed no detectable protein contamination. Complex sugar content, as assayed by Anthrone reaction, was found to be 2mg/ml. Lipid A free polysaccharide was also found to contain 2 mg/ml polysaccharide and it's failure to move on SDS-PAGE (as revealed in the silver stained gels) showed it to be free of contaminating lipid.

Dinitrophenylation of Antigens

K99, LTB and lectins were dinitrophenylated according to the method of Little and Eisen (1967). Briefly, carriers (in 0.1 M carb/bicarb buffer pH 9.5) were reacted with a 0.1 M solution of DNFB (in Acetone) overnight at R.T. The proteins were then dialysed extensively against the coupling buffer. Previous studies by us have shown that 987P has no free amino groups exposed for coupling so a diamino spacer was first linked to the free carboxyl moieties of the protein as follows; 10 mg of purified 987P was precipitated at pH 3.9 by the addition of glacial acetic acid. The pili were removed by centrifugation at 3,000 x g, 10 min at 4C. The pellet was resuspended in dH₂O and the pH raised to 6.5 with 1N NaOH. The pili solution was then reacted with 1-ethyl-3- (3-Dimethylaminopropyl) carbodiimide-HCL (EDAC, Bio Rad Laboratories, Richmond, California), to a final concentration of 0.5 mM in the presence of 20 mM 1,2-diaminoethane (BDH Chemicals Ltd. Poole, England), overnight at room temperature (20-23C). The amino-substituted 987P was dialysed for 24 hrs against two changes of 0.1 M carbonate/bicarbonate buffer pH 9.5 before being used in the subsequent conjugation steps. Lectin binding sites were protected during their reaction with DNFB by the addition of the Lectin specific sugars. Thus, 50 mM solutions of D-glucose, D-mannose, D-glucose, N-acetyl-D-galactosamine, D-galactose, N-acetyl-D-galactosamine, D-gal(1-3)-D-galN-Ac, and L-fucose, were added to the following lectins:- Concanavalin A, Pokeweed mitogen, Lens culinaris, Helix pomatia, Phaseolus vulgaris Glycine max, Arachis hypogea and Ulex eruopeus, respectively.

Antigen administration

Female C57BL/6J mice (18-22 gm) were obtained from the Amino Resources Centre (Perth, Western Australia). All mice were starved for 3-4 hours prior to oral or intramuscular (i.m.) administration of antigens. Mice were fed antigen at appropriate concentrations in 0.5 ml of 0.1M carb/bicarbonate buffer pH 9.5 using a specially prepared feeding needle. Parallel doses of antigen were injected i.m., in 0.1ml of sterile physiological saline, into the left hind leg. Groups of 5 mice receiving antigen either orally or im were given two identical doses of antigen, on day 0 and day 14. A blood sample was taken (approx. 0.5 ml) from the retro-orbital plexus on day 14 and day 21. Mice were then sacrificed by cervical dislocation and gut washes performed on the small intestine in the following manner. The small intestine was carefully removed and a small quantity of washing buffer (1.0 ml, 30 mM Tris.HCl pH 8.8, 0.9% NaCl, 50 mM EDTA plus 1.0% Tween 20) introduced into the lumen of the gut via a blunt ended feeding needle. After gently kneading the intestine the contents were squeezed out through forefinger and thumb. Gut washes so obtained were immediately centrifuged to remove debris and stored at -20C until assayed. Blood samples were allowed to clot at 4C before removal of the serum and storage at -20.

Enzyme Linked Immunosorbent Assay (ELISA)

The ELISA for the determination of antibody titres was performed as described previously by Russell-Jones et al., (1984).

EXAMPLE 1Identification of Molecules Active as Mucosal Immunogens

The possible potential of a number of molecules known to possess the capacity to bind to the intestinal mucosa and to stimulate the production of an immune response after oral administration of these molecules was examined. The response generated by these molecules was compared to the response seen after similar feeding of other molecules having no mucosal binding functions.

As seen in Table 1.1, three broad classes of proteins were detected in these experiments:- those that elicited a serum and intestinal response, K99, 987P, LTB, flu vaccine and the various lectins (Class I) (these shall henceforth be referred to as mucosal immunogens), those that elicited only a serum response (LPS) (Class II) and those that failed to elicit either a serum or intestinal response at the doses tested (Flagellae, BSA and P.S.) (Class III). Within class I antigens 987P was a significantly superior stimulator of IgA antibody (ab) (48.5 ± 1.8) when compared to LTB (12.2 ± 4.4), or K99 (3.2 ± 4.9). In addition 987P also stimulated gastrointestinal IgG (10.8 ± 1.76) to a greater extent than either K99 (3.0 ± 5.3), or LTB (1.0), and only 987P was capable of stimulating serum IgA (10.8 ± 8.8). All four class I antigens stimulated serum IgG to similar degrees (Table 1.1). The class II antigen, LPS, stimulated a small serum IgG response (12.1 ± 1.0) with no concomitant IgA or gastrointestinal reactivity. Finally BSA, flagellae and the polysaccharide moiety of LPS - class III antigens - failed to induce either serum or intestinal IgG or IgA. Representative samples from all three classes; K99, 987P, LTB, LPS and flagellae were administered intramuscularly and screened for both serum and intestinal response (Table 1.2). Class I and II antigens gave similar serum IgG responses yet failed to produce serum IgA or intestinal IgG/IgA Ab responses. Only the anti-LPS serum IgG response appeared significantly improved by i.m. immunisation. Each of 987P, K99 and LTB were further examined in dose response studies after both oral and i.m. administration. As seen in Tables 1.3 and 1.4, 987P yielded consistently higher titers than either K99 or LTB regardless of the route of administration. Interestingly the class I antigen - LTB - displayed a bell shaped dose-response with a plateau maximum between 10 and 50 μ g. None of the other class I antigens produced this effect, nor did the LTB when administered i.m. Oral administration of all class I antigens (Ag) elicited higher levels of intestinal IgA Ab (S-IgA) over the broad range of doses tested. Comparison between the two routes of administration suggests that although i.m. injection consistently gave higher titers, oral administration of mucosal immunogens resulted in comparable levels of antibody production to that obtained by the i.m. route between 10 and 100 μ g of antigen for class I and II antigens.

Table 1.1

Immune reactions to orally presented antigens

Antigen used for immunisation (20 μ g doses)	Serum IgG	Immune response,* day 21.		
		Intestinal IgA	IgG	IgA
K99	968 \pm 120	<4	3.0 \pm 5.2	3.2 \pm 4.9
987P	776 \pm 64	10.8 \pm 8.8	10.9 \pm 1.7	48.5 \pm 1.88
LTB	1351 \pm 211	<4	<4	12.2 \pm 4.4
Flu vac	179 \pm 34	<4	<4	<4
Flagellae	<4	<4	<4	<4
LPS	12.1 \pm 1.0	<4	<4	<4
PS	<4	<4	<4	<4
BSA	<4	<4	<4	<4
Con A**	666 \pm 84	<4	nd	nd
FW-mitogen**	641 \pm 119	<4	nd	nd
L. culinaris**	954 \pm 48	<4	nd	nd
H. pomatia**	591 \pm 127	<4	nd	nd
P. vulgaris**	1378 \pm 110	4.8 \pm 2.3	nd	nd
G. max**	1529 \pm 65	3.1 \pm 6.9	nd	nd
A. hypogea**	1276 \pm 242	<4	nd	nd
U. europeus**	1583 \pm 94	<4	nd	nd

* The reciprocal of the antiserum dilution that gave an ELISA reading of 0.5 after 45 minutes at 37C. Each value represents the mean value obtained from 5 mice \pm 1 standard deviation.

** Each lectin was substituted with 4 DNP molecules/mole lectin. The ELISA titre represents the anti DNP response as measured against DNP-BSA.

Table 1.2

Immune reactions to antigens presented intramuscularly

Antigen used for immunisation (20 µg does)	Immune response,* day 21.			
	Serum		Intestinal	
	IgG	IgA	IgG	IgA
K99	1024 ± 94	<4	<4	<4
987P	1552 ± 112	<4	<4	<4
LTB	1782 ± 100	<4	<4	<4
Flagellae	1595 ± 227	<4	<4	<4
LPS	388 ± 58	<4	<4	<4

* See Table 1.1

Table 1.3

Dose response to orally presented antigens						
Antigen	Immune response*, day 21, per dose (µg)					
	0.1	1.0	10	50	100	1,000
Serum IgG						
K99	1.0	4.0	28	675	1351	4096
987P	4.0	14	84	588	1024	3104
LTB	9.0	194	1351	1331	891	891
Serum IgA						
K99	<4	<4	<4	<4	<4	<4
987P	<4	<4	<4	9.6	18.3	32
LTB	<4	<4	<4	<4	<4	<4
Intestinal IgG						
K99	<4	<4	<4	<4	<4	<4
987P	<4	<4	<4	4.0	4.0	8.0
LTB	<4	<4	<4	<4	<4	<4
Intestinal IgA						
K99	<4	<4	<4	4.0	16.7	87
987P	<4	<4	9.1	54	84	147
LTB	<4	<4	<4	4.0	4.0	8.0

* see Table 1.1.

Table 1.4

Dose response to intramuscularly presented antigens						
Antigen	Immune response*, day 21, per dose (ug)					
	0.1	1.0	10	50	100	1,000
Serum IgG						
K99	256	445	776	1351	1776	5104
987P	256	891	1024	3104	4096	18820
LTB	64	588	1176	2702	4096	8192
Serum IgA						
TK99	<4	<4	<4	<4	<4	<4
987P	<4	<4	<4	<4	<4	<4
LTB	<4	<4	<4	<4	<4	<4
Intestinal IgG						
K99	<4	<4	<4	<4	<4	<4
987P	<4	<4	<4	<4	<4	<4
LTB	<4	<4	<4	<4	7.0	16
Intestinal IgA						
K99	<4	<4	<4	<4	<4	4.6
987P	<4	<4	<4	<4	4.0	6.0
LTB	<4	<4	<4	<4	16.0	11.1

* See Table 1.1.

EXAMPLE 2

Effect of dietary molecules on the immune response to mucosal immunogens upon oral presentation.

Initial studies in our laboratory using outbred Swiss male mice suggested that it was possible to alter the immune response to orally presented antigens by the co-feeding of certain dietary molecules. Accordingly, the mucosal immunogens, K99, 987P and LTB were fed to mice in the presence of a number dietary sugars and vitamins. It was reasoned that as the different antigens were known to bind to different molecules on the surface of the intestinal epithelium, and as it is known that there is a change in the distribution of glycoproteins and glycolipids throughout the length of the gut as well as a change in distribution of absorptive cells, it might be possible to stimulate the uptake of molecules bound to these cells by presenting the antigens in the presence of the specific dietary molecule normally taken up by these cells. An extension to this argument would be that the profile of stimulatory molecules would change from antigen to antigen.

The results represented in tables 2.1, 2.2 and 2.3 demonstrate that although most of the vitamins and sugars have had some effect in modulating the immune response to K99, 987P and LTB, some dietary molecules appear to be selective as to which mucosal immunogen they appeared to influence but also as to whether they induced primarily a secretory or serum response. Thus, the serum antibody response to K99 was significantly increased ($P<0.05$) by co-administration with Vit B12 of Melibiose, unchanged when given with Vit B2, Vit D, Vit E, Fructose or Mannose and decreased to varying extents with Vit A, Vit B1, Vit B6, Vit C, Lactose, Sorbitol and Xylose (Table 2.1).

In contrast, the serum Ab response to oral 987P (Table 2.2) was elevated when 987P was co-administered with Vit B6, Vit B12, Vit C, Vit E, Fructose or Mannose, it was unchanged with Vit A, Vit B1, Vit B2, Lactose, Melibiose, Sorbitol and Xylose, and decreased in the presence of Vit D. LTB on the otherhand, displayed a unique profile for the effect of co-feeding of dietary molecules on the serum Ab levels. The results in Table 2.3 clearly show an augmented serum titer to LTB in the presence of Vit A, Vit B2, Vit D, Fructose, Mannose and Xylose. Little or no change with Vit B1, Vit B12, Vit C or Melibiose and almost complete inhibition with Vit B6, Vit E, Lactose, Melibiose and Sorbitol. The inhibition of an immune response seen with Vit B6, Lactose, Melibiose and Sorbitol is to be expected due to the similarities in

structure of these compounds to Galactose which is claimed to be the specific sugar determinant on the GM1 ganglioside to which LTB is known to bind. These results are broadly suggestive that K99, 987P and LTB bind to and are internalized by discrete cells of the microvillous epithelium.

Dose response experiments (Tables 2.4, 2.5 and 2.6) demonstrate that it is possible to stimulate the secretory arm of the immune system without concomitant stimulation of serum antibodies, or conversely to augment the serum response without affecting the level of secretory Abs, by the simple addition of dietary molecules to the orally presented mucosal immunogens. Thus cofeeding of large doses of Vit B12 or melibiose with K99 leads to a two to eightfold (respectively) increase in serum Ab with little concomitant increase in secretory Abs. Conversely cofeeding of Vit D in increasing doses lead to a drop in serum Abs and a rise in secretory Ab. Certain dietary molecules on the other hand also result in stimulation of both secretory and serum Ab titres as shown by an eightfold increase in serum Ab and a 1000 fold increase in S-IgA upon cofeeding of Vit C with 987P.

Experiments in which the mucosal immunogens were injected i.m. together with vitamins or sugars showed little effect if any on the immune response thus demonstrating that the change in response due to cofeeding of these molecules with the mucosal immunogens must occur on or near the site of absorption of these molecules rather than directly upon the immune system (Table 2.7).

TABLE 2.1

Effects of dietary molecules on the immune response to orally administered K99 (20 μ g)*					
Dietary Molecule	Dose	Antibody Response			
		Serum		Intestinal	
		IgG	IgA	IgG	IgA
none	-	968 \pm 120	<4	3.0 \pm 5.2	3.2 \pm 4.9
Vit A	20 μ g	278 \pm 184	3.4 \pm 4.7	1.5 \pm 1.1	5.4 \pm 3.0
Vit B1	"	117 \pm 107	1.5 \pm 2.0	2.7 \pm 1.0	2.1 \pm 0.9
Vit B2	"	604 \pm 216	<4	2.3 \pm 1.7	2.0 \pm 0.6
Vit B6	"	14 \pm 50	<4	2.0 \pm 1.5	3.5 \pm 8.2
Vit B12**	"	3377 \pm 1266	4.0 \pm 3.0	<4	<4
Vit C**	"	318 \pm 255	2.0 \pm 2.8	32 \pm 1.1	98 \pm 70
Vit D**	"	1921 \pm 640	<4	<4	6.3 \pm 2.7
Vit E	"	512 \pm 128	<4	<4	4.4 \pm 2.1
Fructose	50mM	1782 \pm 966	8.4 \pm 3.7	2.9 \pm 1.6	34.7 \pm 14.2
Lactose	"	84 \pm 204	<4	<4	22.9 \pm 6.7
Mannose	"	1176 \pm 411	2.6 \pm 3.4	10.2 \pm 3.4	21.1 \pm 40.3
Melibiose**	"	1840 \pm 208	1.2 \pm 1.4	3.2 \pm 2.0	4.4 \pm 3.7
Sorbitol	"	77 \pm 179	<4	1.3 \pm 0.4	20.5 \pm 3.4
Xylose	"	328 \pm 217	<4	1.9 \pm 1.1	2.8 \pm 1.3

* The reciprocal of the antiserum dilution that gave an ELISA reading of 0.5 after 45 min at 37°C on day 21 after immunisation. Each value is the mean of five mice \pm 1 standard deviation.

** Each value is the mean of 15 mice \pm 1 standard deviation. These molecules were also tested in dose response experiments.

TABLE 2.2

Effects of dietary molecules on the immune response to oral 987P (20 μ g)*					
Dietary Molecule	Dose	Antibody Response			
		Serum		Intestinal	
		IgG	IgA	IgG	IgA
none	-	776 \pm 64	10.8 \pm 8.8	10.9 \pm 1.7	48.5 \pm 1.8
Vit A**	20 μ g	648 \pm 40	29.0 \pm 20	8.4 \pm 3.1	20.5 \pm 24.6
Vit B1	"	891 \pm 127	12.1 \pm 3.6	9.4 \pm 1.5	14.7 \pm 5.5
Vit B2	"	1082 \pm 271	31.1 \pm 11.9	17.8 \pm 7.6	21.1 \pm 11.9
Vit B6	"	1782 \pm 509	23.6 \pm 8.7	32.8 \pm 9.3	39.9 \pm 7.1
Vit B12	"	3983 \pm 1307	48.5 \pm 16.0	35.7 \pm 3.4	91.7 \pm 31.9
Vit C**	"	4521 \pm 1046	54.2 \pm 19.2	10.8 \pm 6.9	84.1 \pm 14.3
Vit D**	"	398 \pm 89	18.8 \pm 11.0	13.1 \pm 4.9	34.7 \pm 8.1
Vit E	"	3468 \pm 776	9.18 \pm 2.6	11.1 \pm 4.2	19.9 \pm 3.9
Fructose	50mM	2048 \pm 894	10.8 \pm 3.6	15.1 \pm 4.7	23.5 \pm 3.2
Lactose	"	1128 \pm 662	15.3 \pm 2.9	19.6 \pm 2.5	21.7 \pm 6.1
Mannose	"	4970 \pm 2270	24.9 \pm 11.7	14.3 \pm 1.9	16.9 \pm 26.4
Melibiose**	"	1243 \pm 474	30.3 \pm 7.7	91.7 \pm 10.9	124.5 \pm 22.6
Sorbitol**	"	1389 \pm 307	38.8 \pm 19.1	22.9 \pm 4.6	91.7 \pm 18.6
Xylose	"	1024 \pm 941	6.2 \pm 1.9	19.6 \pm 7.1	21.4 \pm 5.4

* See Table 2.1

** See Table 2.1

TABLE 2.3

Effects of dietary molecules on the immune response to oral LTB (20 μ g)*					
Dietary Molecule	Dose	Antibody Response			
		Serum		Intestinal	
		IgG	IgA	IgG	IgA
none	-	1351 \pm 211	<4	<4	12.2 \pm 4.4
Vit A	20 μ g	4705 \pm 676	<4	<4	21.1 \pm 7.6
Vit B1	"	1782 \pm 309	<4	<4	16.0 \pm 2.1
Vit B2	"	3565 \pm 908	<4	<4	16.0 \pm 3.7
Vit B6**	"	9.18 \pm 1.1	<4	<4	<4
Vit B12	"	1024 \pm 116	<4	<4	24.2 \pm 11.9
Vit C	"	337 \pm 206	<4	<4	16.1 \pm 5.0
Vit D	"	4097 \pm 74	<4	<4	13.9 \pm 2.2
Vit E	"	194 \pm 64	<4	<4	18.4 \pm 3.6
Fructose	50mM	6208 \pm 1192	<4	<4	10.5 \pm 3.3
Lactose**	"	5.0 \pm 1.0	<4	<4	<4
Mannose	"	4096 \pm 658	<4	<4	24.2 \pm 8.1
Melibiose	"	512 \pm 76	<4	<4	8.0 \pm 4.0
Sorbitol**	"	8.0 \pm 1.2	<4	<4	<4
Xylose	"	5404 \pm 2211	<4	<4	21.1 \pm 9.2

* See Table 2.1

** See Table 2.1

TABLE 2.4

Effect of orally administered dietary molecules on the immune response to oral antigen (K99)*								
Dietary Molecule	Day 21 Immune response per dose (μg ~, mM +)							
	0.1	1.0	10	50	100	500	1000	
Serum IgG								
Vit B12	256	675	1176	1552	2352	nd	2352	
Vit C	512	891	588	675	1024	nd	891	
Vit D	588	588	776	891	1782	nd	891	
Melibiose	128	256	675	4096	9410	256	nd	
Serum IgA								
Vit B12	<4	<4	4.0	5.2	<4	nd	<4	
Vit C	<4	<4	4.0	16.0	16.0	nd	16.0	
Vit D	<4	<4	<4	<4	<4	nd	<4	
Melibiose	<4	<4	<4	4.0	4.0	4.0	nd	
Intestinal IgG								
Vit B12	<4	<4	<4	<4	<4	nd	<4	
Vit C	<4	4.0	16.2	32.0	36.1	nd	38.0	
Vit D	<4	<4	<4	<4	<4	nd	<4	
Melibiose	<4	<4	<4	4.0	4.0	4.5	nd	
Intestinal IgA								
Vit B12	<4	<4	<4	<4	5.2	nd	13.9	
Vit C	<4	<4	4.0	16.0	36.7	nd	73.5	
Vit D	<4	<4	4.0	8.0	13.9	nd	24.2	
Melibiose	5.2	4.0	4.0	4.0	9.2	4.0	nd	

~, dose in μg , vitamins;

+, dose in mM, sugars.

* See Table 2.1

TABLE 2.5

Effect of orally administered dietary molecules on the immune response to oral antigen (987P)								
5	Dietary Molecule	Day 21 Immune response per dose (ug ~,mM +)						
		0.1	1.0	10	50	100	500	1000
Serum IgG								
10	Vit A	512	675	388	891	675	nd	588
	Vit C	891	1351	4096	8192	8192	nd	9410
	Vit D	2352	2048	256	73	147	nd	1351
	Melibiose	512	481	463	1250	1006	1292	nd
	Sorbitol	873	1133	1024	1400	2123	85	nd
Serum IgA								
15	Vit A	<4	<4	16.0	30.0	36.0	nd	64.0
	Vit C	4.0	4.0	32.0	66.0	73.1	nd	86.7
	Vit D	64	16.0	16.0	16.0	28.0	nd	38.1
	Melibiose	nd	nd	nd	nd	nd	nd	nd
	Sorbitol	nd	nd	nd	nd	nd	nd	nd
Intestinal IgG								
20	Vit A	<4	<4	4.6	17.2	16.1	nd	16.0
	Vit C	<4	<4	16.0	6.0	5.2	nd	16.0
	Vit D	<4	<4	<4	12.2	14.6	nd	14.0
	Melibiose	5.0	27	75	76	38.3	4.3	nd
	Sorbitol	50	74	64	93	294	257	nd
Intestinal IgA								
25	Vit A	<4	<4	4.0	26.9	32.1	nd	16.0
	Vit C	<4	4.6	55	337	1024	nd	776
	Vit D	<4	<4	16.0	147	25.2	nd	36.7
	Melibiose	7.6	39	65	159	58.0	16.0	nd
	Sorbitol	52	51	67	111	178	180	nd

~, dose in ug, vitamins;

+, dose in mM, sugars

* see Table 2.1

TABLE 2.6

Effect of orally administered dietary molecules on the immune response to oral antigen (LTB)*							
Dietary Molecule	Day 21 Immune response per dose (ug ~,mM +)						
	0.1	1.0	10	50	100	500	1000
Serum IgG							
Vit B6	2352	5048	55.7	10.5	4.6	nd	4.0
Lactose	1782	1782	73.5	6.9	4.0	4.0	nd
Sorbitol	1024	256	18.3	13.9	4.0	4.0	nd
Serum IgA							
Vit B6	<4	<4	<4	<4	<4	nd	<4
Lactose	<4	<4	<4	<4	<4	<4	nd
Sorbitol	<4	1.4	<4	<4	<4	<4	nd
Intestinal IgG							
Vit B6	<4	<4	<4	<4	<4	nd	<4
Lactose	<4	<4	<4	<4	<4	<4	nd
Sorbitol	<4	<4	<4	<4	<4	<4	nd
Intestinal IgA							
Vit B6	5.6	<4	<4	<4	<4	nd	<4
Lactose	4.0	4.0	<4	<4	<4	<4	nd
Sorbitol	4.0	<4	<4	<4	<4	<4	nd

~, dose in ug, vitamins;

+, dose in mM, sugars

* see Table 2.1

TABLE 2.7

Effect of varying the dose of co-administered dietary molecules on the immune response to intramuscularly presented antigen K99, 987P*							
Antigen given	Dietary molecule	Day 21 Immune response					
	(ug)	0.1	1.0	10	50	100	1000
(s) IgG							
K99	Vit B12	1121	1468	1572	2328	4766	2109
K99	Vit D	1024	1272	1168	1372	1489	1315
987P	VIt C	1687	1529	1707	1700	1662	1891
	(mM)	0.1	1.0	10	50	100	500
(s) IgG							
K99	Melibiose	1024	1176	1057	1392	1262	989
987P	Melibiose	1538	1622	1701	1519	1666	1621
987P	Sorbitol	1670	1577	1548	1632	1711	1651

+. no serum IgA, intestinal IgG or intestinal IgA was detected

* See Table 2.1

EXAMPLE 3

The two previous examples demonstrated that small doses of orally administered mucosal immunogens have the capacity to induce significant serum IgG titers with or without a parallel rise in secretory IgA antibody levels. Furthermore, it was shown that the immune response can be tailored by the co-administration of dietary molecules. The finding that the lectins used in the first study were capable of acting as carriers to prime for an anti-DNP response suggested that the potential exists for at least some of these mucosal immunogens to act as "carriers" for other antigens, therefore improving the relatively poor uptake of most antigens across the intestinal epithelium.

The following study was designed to investigate whether this carrier potential exists and to establish some of the various parameters for its successful use as a means of formulating new and more effective oral vaccines and/or orally administered drugs.

Materials and MethodsConjugation of antigens to the mucosal immunogensDinitrophenylation of carriers

DNFB was reacted with Lectins and carrier as described above (see general methods)

Lipopolysaccharide (LPS) and polysaccharide (PS) conjugation

S. typhimurium LPS and PS were purified as described previously (accompanying examples). LPS and PS were coupled to the MI using the periodate method (Avrameus and Ternynck, 1971).

Glutaraldehyde coupling

Luteinizing hormone releasing hormone (LHRH), bovine serum albumin (BSA) (From Sigma Chemical co. St. Louis, Miss) and *S. typhimurium* flagella were individually coupled to MI using the two step glutaraldehyde procedure of Avrameus et al (1978). Briefly, the required protein was reacted with 0.2% glutaraldehyde for 2 hrs at R.T. proteins were dialysed overnight against carb/bicarb buffer pH 9.5 followed by the addition of MI at molar ratio's of 5, 10, 20 and 40:1, Antigen:MI, as required and reacted for 24 hrs at RT. Finally ethanclamine (Sigma) was added to a final concentration of 0.1M, (1 hr, RT) followed by overnight dialysis at 4C against 0.1 M carb/bicarb buffer pH 9.5.

Peroxidase conjugated lectins

Commercial preparations of peroxidase conjugated to the lectins from *Glycine max*, *Arachis hypogaea*, *Tetragonolobus purpureas* and concanavalin A were purchased from Sigma.

Chemical synthesis of LHRH conjugates

LHRH was conjugated to LTB using the glutaraldehyde procedure outlined above. Glutaraldehyde activated LHRH was added to LTB at a ratio of 20:1 LHRH:LTB and allowed to couple O/N at R.temp. The resultant conjugate was dialysed extensively against 0.1 M Carb/bicarb buffer pH 9.5 before feeding. Controls consisted of LHRH or LTB which had been treated with glutaraldehyde alone.

TABLE 3.1

Antibody response to DNP-modified mucosal immunogens.					
Immunogen	Dose (ug)	Immune response*			
		Anti-DNP		Anti-Carrier	
		serum IgG	Int IgA	serum IgG	Int IgA
K99	20	<4	<4	875±62	3.9±5.1
K99	100	<4	<4	1351±128	16.7±2.3
DNP6.K99	20	21±10.5	<4	64±7.2	<4
DNP18.K99	500	1024±77	42±9.6	128±27.4	76±12.9
DNP1.8.K99	500	1176±164	28±14.4	3565±192	88±21.0
987P	20	<4	<4	891±76	27.8±13.6
987P	100	<4	<4	1024±89	84±22.4
DNP6.987P	20	24±3.1	<4	147±12.2	<4
DNP25.987P	500	1024±244	14±3.1	111±34.1	68±19.2
DNP2.5.987P	500	1351±196	7±1.4	2048±166	128±38.4
LTB	20	<4	<4	1351±211	12.2±4.4
DNP2.3.LTB	20	24.3±5.6	<4	445±35	<4
LTB	100	<4	<4	891±56	4.0
DNP6BSA	20	<4	<4	<4	<4
DNP6BSA	100	<4	<4	<4	<4
Con A**	20	666±84	<4	nd	nd
PW-mitogen**	20	641±119	<4	nd	nd
L. culinaris**	20	954±48	<4	nd	nd
H. pomatia**	20	591±127	<4	nd	nd
P. vulgaris**	20	1378±110	4.8±2.3	nd	nd
G. max**	20	1529±65	3.1±6.9	nd	nd
A. hypogea**	20	1276±242	<4	nd	nd
U. europeus**	20	1583±94	<4	nd	nd

* The reciprocal of the antiserum dilution that gave on ELISA reading of 0.5 after 45 min at 37C. Each value represents the mean of 5 mice ±1 standard deviation.

** Each lectin was substituted with 4 DNP groups

TABLE 3.2

Carrier potential of K99 for various antigens

			Immune Response*				
	Immunogen	Molar Dose	Antigen	Carrier			
		Ratio	(μ g)	Serum IgG	Int IgA	Serum IgG	Int IgA
10							
	K99	-	20	<4	<4	875 \pm 62	3.9 \pm 5.1
	K99	-	100	<4	<4	1351 \pm 94	16.7 \pm 2.8
15	BSA-K99	1:4	20	<4	<4	<4	<4
	BSA-K99	1:5	500	<4	<4	73.5 \pm 11.2	<4
	BSA-K99	1:10	500	<4	<4	147 \pm 48.2	<4
20	BSA-K99	1:20	500	222 \pm 47	126 \pm 29.2	3809 \pm 226	84 \pm 16.6
	BSA-K99	1:40	500	73 \pm 19.6	44 \pm 7.5	3176 \pm 391	64 \pm 11.9
	Flag-K99	1:5	20	<4	<4	<4	<4
	LPS-K99	1:1**	20	<4	<4	<4	<4
25	PS-K99	1:1**	20	<4	<4	229 \pm 101	5.2 \pm 2.6
	BSA	-	20	<4	<4	-	-
	Flagellae	-	20	<4	<4	-	-
30	LPS	-	20	12.1 \pm 2.7	<4	-	-
	PS	-	20	<4	4.2 \pm 0.4	-	-

* See Table 3.1

** Ratio based on weight.

TABLE 3.3

Carrier potential of 987P for various antigens

Immunogen	Molar Dose	Ratio (µg)	Immune Response*			
			Antigen	Carrier		
			Serum IgG	Int IgA	Serum IgG	Int IgA
987P	-	20	<4	<4	891±76	27.8±13.6
987P	-	100	<4	<4	1024±83	84±26.7
BSA-987P	1:4	20	<4	<4	84±2.6	<4
BSA-987P	1:5	500	<4	<4	256±49	<4
BSA-987P	1:10	500	29.8±7.4	4.6±2.2	675±110	<4
BSA-987P	1:20	500	306±88	122±47.6	4263±408	194±38.6
BSA-987P	1:40	500	124±47	110±38.4	4705±521	156±55
Flag-987P	1:5	20	1552±361	<4	-	-
LPS-987P	1:1**	20	<4	<4	194±28.6	<4
PS-987P	1:1**	20	<4	<4	337±96	5.2±6.8
BSA	-	20	<4	<4	-	-
Flagellae	-	20	<4	<4	-	-
LPS	-	20	12.1±2.7	<4	-	-
PS	-	20	<4	4.2±0.4	-	-

* See Table 3.1

** Ratio based on weight.

TABLE 3.4

Effects of altering dosage of substituted carrier on the immune response			
Antigen	Dose (µg)	Immune Response (Serum IgG)*	
		Anti-BSA	Anti-Carrier
BSAO.03.K99	70	13.9±4.4	776±148
BSAO.03.K99	140	36.7±14.6	1782±174
BSAO.03.K99	280	73.5±22.1	1989±215
BSAO.05.987P	70	36±2.6	891±109
BSAO.05.987P	140	168±23.7	1552±176
BSAO.05.987P	280	337±43.7	2042±180

* See Table 2.1

TABLE 3.5

Effect of chemically conjugated LHRH-LTB on reproductive organs of the female mouse*							
Conjugate	Coupling	Route procedure	Dose	No	Body (μ g)	Ovaries Mice weight	%Body wt
+ uterus	O + U/tot						
LHRH-LTB	glut	os/os	20	5	21.19	0.03	0.17%
LHRH-LTB	glut	os/os	50	5	21.16	0.04	0.23%
LHRH	glut	os/os	50	6	20.13	0.11	0.62%
LTB	glut	os/os	50	3	18.18	0.14	0.76%
LHRH-LTB	glut	im/im	50	6	20.16	0.16	0.97%
LHRH,LTB	mix	os/os	50	7	27.32	0.15	0.55%
LHRH,LTB	mix	im/im	50	7	30.07	0.26	0.73%
LTB	-	os/os	50	7	28.26	0.24	0.87%
-	-	os/os	-	5	19.19	0.16	0.82%

* Animals received antigen on days 0 and 14. On day 28 mice were euthanased and their reproductive tracts weighed.

TABLE 3.6

Effect of genetically constructed LHRH conjugates on the reproductive organs of the female mouse					
Conjugate	Route	Dose (μ g)	Body weight	Ovaries + uterus	%Body wt O + U/tot*
B-gal-(LHRH)3.5	im/im	20	19.47	0.10	0.49
B-gal-(LHRH)3.5	im/im	20	18.44	0.10	0.56
B-gal-(LHRH)3.5	im/im	50	19.39	0.10	0.54
LTB-(LHRH)3.5	os/os	20	19.35	0.08	0.39
LHRH	os/os	20	19.34	0.10	0.44
LHRH	im/im	20	19.39	0.15	0.76
-	im/im	-	17.74	0.08	0.46
-	os/os	-	18.63	0.11	0.60

For all intramuscular injections antigens were administered in montanide. Im/im controls received montanide/saline mixtures.

* Animals received antigen on days 0 and 14. On day 28 mice were euthanased and their reproductive tracts weighed.

Genetic fusion of LHRH to B-galactosidase and LTB

CONSTRUCTION OF A PLASMID VECTOR EXPRESING A FUSED LTB/LHRH HYBRID POLYPEPTIDE

1. DNA Fragment Containing LTB Coding Sequences

A Hind III fragment was obtained from a pBR322 based plasmid containing the cloned LTB gene (Leong et al, 1985), from the plasmid NP307 in *E. coli* strain RC411 (Dallus et al, 1979) which had been modified, using a Spe I site near the stop codon for LTB, and then mung bean nuclease digestion, using standard conditions. (Unless specified otherwise, the conditions used for standard recombinant DNA techniques and nucleic acid modifying nzym s are as described in Molecular Cloning, A Laboratory Manual, Maniatis, Fritsch and Sambrook. Cold Spring Harbor Laboratory, 1982). This eliminated th stop codon normally found after amino acid 123 in LTB, removing 9 base pairs of DNA and fortuitously generating a Hind III site as shown below:

10

15

20

25

- 30



40

45

50

55

N terminus of β -galactosidase, α fragment

```

Met Thr Met Ile Thr Asn Ser Ser Ser Val Pro Leu Arg
5  ATG ACC ATG ATT ACG AAT TCG AGC TCG GTA CCC CTT CGA
      EcorI
Pro Gly Glu His Trp Ser Tyr Gly Leu Arg Pro Gly
10  CCC GGG GAG CAC TGG TCC TAC GGC CTT CGA CCC GGG
      <-----1----->
Clu His Trp Ser Tyr Gly Leu Arg Pro Gly Glu His Trp
15  GAG CAC TGG TCC TAC GGC CTT CGA CCC GGG GAG CAC TGG
      <-----2-----> <-----
Ser Tyr Gly Leu Arg Pro Gly Gly Asp Pro Leu Glu Ser Thr
20  TCC TAC GGC CTT CGA CCC GGG GGG GAT CCT CTA GAG TCG ACC
      3 -----> HincII

```

The DNA sequence confirmed the insertion of DNA from the synthetic oligonucleotides to place an in-frame fusion of approximately 3 and a half repeats of the LHRH encoding sequence (34 amino acids). The complete LHRH coding blocks are indicated by the arrows.

The replicative from DNA of P29 was digested with EcoRI and HincII (sites indicated in DNA sequence above), and end filled using standard conditions. The small 140 base pair fragment was isolated from a polyacrylamide gel.

30 3. Construction of the LTB/LHRH Fusion Vector

The pUC13 plasmid containing the LTB coding sequence inserted in the HindIII site (section 1 above) was digested with Sall, end filled and phosphatased using standard conditions. The vector DNA was then ligated to the end filled EcoRI/HincII fragment from P29 (Section 2 above). The fusion should have the amino acid sequence below. aal - 122 (lys)-ala-trp-ala-ala-gly-arg-asn-ser-ser-ser-val- pro-LTB coding sequence.

```

40  leu-arg-pro-gly-[glu-his-trp-ser-tyr-gly-leu-arg-pro-gly]3-
      LHRH
gly-asp-pro-leu-glu-ser-arg-leu
45

```

There is a stop codon 24 bases beyond the LHRH sequence which defines the production of a 176 amino acid polypeptide, with 122 amino acids from LTB, 34 amino acids encoding the LHRH repeat, and an additional 20 amino acids derived from the adjoining regions.

The correct construct was screened by digesting DNA from minipreps with Eco RI and looking for plasmids with the appropriately larger Eco RI fragment. The putative positives were further screened for the expression of this polypeptide, driven from the lac promoter of pUC13. Bacterial extracts are analysed on polyacrylamide gels followed by transfer to nitrocellulose paper and Western blotting with rabbit antisera directed against an LTB and LHRH conjugate. A peptide of the expected size was detected by both antisera.

4. Construction of expression plasmid K66 and expression strain BTA1185

A 573 bp Eco RI fragment of the pUC13 LTB-LHRH fusion plasmid described in 3, which contains the LTB-LHRH fusion coding region in its entirety, was isolated from an agarose gel and ligated into Eco RI cut, phosphatased expression vector pKK223-3 (from Pharmacia). The resultant expression plasmid PBTA K66, placed the expression of the fusion protein under the control of the tac promoter, where expression is induced with IPTG. The plasmid was transformed into *E. coli* host strain JM101 (SupE, thi, (lac-pro AB) [F' traD36, pro AB lacI^q Z M 15] to give the host vector expression system BTA1185.

5. Production and Purification of LTB/LHRH Fusion Protein for Animal Trials.

The LTB(LHRH)_{3.5} producing strain was grown as described previously. After induction with IPTG for 2 h bacteria were pelleted by centrifugation (3,000 x g, 10 min at 4°C). Bacteria were then resuspended in dH₂O and lysed in a French Press. After removal of the bacterial debris by centrifugation (18,000 x g, 10 min, at 4°C) the supernatant was loaded onto an agthio-galactose column (Sigma). The fusion protein was then eluted with 0.5M galactose and dialysed against 0.1M carb/bicarb buffer pH 9.5.

Antigen administration and measurement of the immune response

All oral presentation procedures, antibody collections and ELISA determinations were as described previously.

RESULTS

Demonstration of the carrier potential of the mucosal immunogens

All of the mucosal immunogens tested showed the capacity to effectively transport the covalently attached hapten DNP across the intestinal mucosa and to elicit a serum anti-DNP Ab response after feeding of the dinitrophenylated-MI. DNP-modified BSA, however was completely ineffective in eliciting an anti-DNP or anti-BSA response when fed at the concentrations tested (Table 3.1). Initial experiments in which K99 and 987P were complexed to much larger molecules than DNP were unsuccessful in generating immune responses to either the mucosal immunogen or to the molecule coupled to it (Tables 3.2 & 3.2), possibly due to steric interference in the binding of the pili to the mucosal epithelium. It was therefore decided to vary the ratio of antigen to MI. When various ratios of BSA:pili were tested, it was found that when ratios of greater than 1:20 BSA:pili were fed it was not possible to generate either anti-BSA or anti-pili responses even with a dose of 500 ug, demonstrating that it was not possible for the complexes to effectively associate with the mucosal epithelium and to therefore generate an immune response. However when ratios of 1:20 or 1:40 were employed good responses to both BSA and to pili were observed (Tables 3.2 & 3.3). The magnitude of the immune response was readily varied by altering the doses of complex fed

Oral administration of LHRH coupled to LTB lead to a significant reduction in the combined uterine and ovarian weights of female mice receiving either 20 or 50 ug LHRH-LTB (P 0.05) (Table 3.5,3.6). No such weight loss was seen with either LHRH or LTB fed alone or together or to intramuscular injection of LHRH-B-galactosidase, LHRH-LTB, or free LHRH. The effect of the weight loss was also seen developmentally as there was a complete absence of mature follicles in the ovaries, thus, the animals were effectively "castrated". There was a slight reduction in reproductive tract weights when mice were fed the genetically constructed LTB-(LHRH)_{3.5} fusion protein (Table 3.6) but in this experiment, the reduction was not significant at the doses tried.

EXAMPLE 4

Induction of cell-mediated immunity after oral administration of antigen

Feeding of mucosal immunogens was shown to be effective in eliciting humoral responses as measured by the production of serum and intestinal antibodies. It was not known, however whether there was a concomitant stimulation of a cell mediated immune (CMI) response to the mucosal immunogens.

The following study was designed to compare the CMI generated by oral presentation of a mucosal immunogen with that generated by classic subcutaneous (s.c.) injection of antigen in Complete Freund's

Adjuvant (CFA).

Methods

Male C57B1/6J mice were immunized by feeding 20 µg antigen in 0.1 M carb/bicarb buffer pH 9.65 or by injecting 20 µg antigen in CFA s.c. Controls received only buffer or adjuvant. Seven days after immunization mice were injected in the left back footpad with 10 µg of antigen in 20 µl saline, and injected with 20 µl saline alone in the right rear footpad. After a further 24 hours, the difference in thickness between the left and right rear footpads was measured using a micrometer.

Results

The results shown in table 4.1 demonstrates that a good cellular immune response is generated upon oral feeding of either 987P or LTB mucosal immunogens. In fact the response was surprisingly high as it was only slightly smaller than that generated by the s.c. injection of these antigens in CFA.

Table 4.1

Generation of a cell mediated immune response upon oral presentation of mucosal immunogens.			
Antigen	Control	Immunisation route	
		Oral	Subcutaneous
987P	11 ± 2	31 ± 6.6	38 ± 5
LTB	5 ± 4.5	14 ± 3.7	26 ± 5.8

* Results represent the increase in footpad size after immunization with antigen. Results are the mean of 5 mice ± standard deviation.

INDUSTRIAL APPLICABILITY

Industrial applications of the invention include the preparation of oral medicaments for administration to vertebrate hosts.

Potential Vaccine Candidates for Oral Vaccine

Allergens: Various Grass Pollens: barley, couch
Weed Pollens: clover, dock
Tree Pollens: ash, cyprus
Plant Pollens: broom
Epithelia: car hair, dog hair, pig hair
Miscellaneous: house dust, wheat chaff, Kapok.

Hormones: LHRH, FSH, HGH, Inhibin

Vaccines: Haemagglutinins from
Influenza, Measles, Rubella, Smallpox, Yellow Fever, Diphtheria, Tetanus, Cholera, Plague, Typhus, BCG, Haemophilus influenzae, Neisseria catarrhalis, Klebsiella pneumoniae, Pneumococci, streptococci esp. S. mutans.

Pili from: E. Coli, N. gonorrhoeae, N. meningitis, N. catarrhalis, Yersinia spp., Pseudomonas aeruginosa, Pseudomonas spp., Moraxella bovis, Bacteroides nodosus, Staphylococci spp., Streptococci spp., Bordetella spp.

REFERENCES

- AVREMEAS, S., Ternynck, T. & Geudson, J.-L. 1978 Coupling of enzymes to antibodies antigens. Scand. J. Immunol., 8, suppl. 7, 7-23.
- AVRAMEAS, S. & Ternynck, T. 1971 Peroxidase labelled antibody and Fab conjugate with enhanced intracellular penetration. Immunochem., 8, 1175-1179.

- BEFUS, A.D., and J. Bienenstock. 1982. Factors involved in symbiosis and host resistance at the mucosa-parasite interface. *Prog. Allergy*. 31 : 76.
- BIENENSTOCK, J., and A.D. Befus. 1980. Mucosal Immunology. *Immunology*. 41 : 249.
- BLAKE, M.S., and E.C. Gotschlich. 1984. Purification and partial characterization of the opacity-associated proteins of *Neisseria gonorrhoeae*. 159 : 452.
- 5 BLAND, P.W. & Britton, D.C. (1984) Morphological study of antigen-sampling structures in the rat large intestine. *Infect. Immun.*, 43, 693-699.
- CLARK, S., A. Cahill, C. Stirzaker, P. Greenwood and R. Gregson. 1985. Prevention by vaccination-animal bacteria, p. 481-487. In S. Tzipori (ed.) *Infectious diarrhoea in the young*. Elsevier Science Publishers B.V.
- 10 CONTEY, J.R., and L.R. Inman. 1981. Diarrhea due to *Escherichia coli* strain RDEC-1 in the rabbit. The Peyer's patch as the initial site of attachment and colonization. *J. Infect. Dis.* 43 : 440.
- DALLAS' et. al. (1979) Cistrons encoding *Escherichia coli* heat labile toxin *J. Bact.* 139 850-858.
- ELSON, C.O. & EALDING, W. (1984a) Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. *J. Immunol.*, 132, 2736-2741.
- 15 ELSON, C.O. & EALDING, W. (1984b) Cholera toxin did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated antigen. *J. Immunol.* 133, 2892-2897.
- EVANS, D.G. & Evans, D.J. (1978) New surface-associated heat-labile colonization factor antigen (CFA/II) produced by enterotoxigenic *Escherichia coli* of serogroups O6 and O8. *Inf. Immun.*, 21, 638-647.
- De GRAAF, F.K., P. Klemm, and W. Gaastra. 1981. Purification, characterization and partial covalent structure of the adhesive antigen K99 of *Escherichia coli*. *Infect. Immun.* 33 : 877.
- 20 De GRAAF, F.K. & Roorda, I. (1982) Production, purification, and characterization of the fimbrial adhesive antigen F41 isolated from calf enteropathogenic *Escherichia coli* strain B41M. *Infect. Immun.*, 36, 751-758.
- FUJITA, K. & Finkelstein, R.A. 1972 Antitoxic immunity in experimental Cholera. *J. Infect. Dis.*, 125, 647-655.
- 25 FUSCO, P., A. To, S. To, and C. Brinton, Jr. 1978. The purification and characterisation of four types of *E. Coli* pili and the specificity of *E. coli* pili for immunity colonization and adhesion, p. 60-70. In C. Miller (ed.), XIIIth U.S. Japan Conference on Cholera, Atlanta, Ga., 1977. National institution of Health, Bethesda, Md.
- GAASTRA, W., and F.K. de Graaf. 1982. Host specific fimbrial adhesion of noninvasive enterotoxigenic *Escherichia coli* strains. *Microbiol. Rev.* 46 : 129.
- 30 GAASTRA, R.A. (1975) An attempt to identify the intestinal receptor for the K88 adhesin by means of a haemagglutination inhibition test using glycoproteins and fractions and sow colostrum. *J. Gen. Microbiol.*, 86, 228-240.
- GIBBONS, R.A. (1975) An attempt to identify the intestinal receptor for the K88 adhesin by means of a haemagglutination inhibition test using glycoproteins and fractions from sow colostrum. *J. Gen. Microbiol.*, 86, 228-240.
- 35 HANSON, D.G., VAZ, N.M., MAIA, L.C.S. & LYNCH, J.M., (1979) Inhibition of specific immune responses by feeding protein antigens. *J. Immunol.*, 123, 2337-2343.
- HERBERT, D., P.J. Phipps, and R.E. Strange. 1985. Carbohydrate analyses, determination of total carbohydrate, p. 265-279. In J.R. Norris, and D.W. Ribben (ed.), *Methods in Microbiology*. v. 5B.
- 40 ISAACSON, R.E., J. Colmenero, and P. Richter. 1981. *Escherichia coli* K99 pili are composed of one subunit species. *FEMS Microbiol. Lett.* 12 : 229.
- ISAACSON, R.E., and P. Richter. 1981. *Escherichia coli* 987P Pilus. Purification and partial characterization. *J. Bacteriol.* 146 : 784.
- 45 KLIPSTEIN, F.A., ENGERT, R.F., & SHORT, H.B. (1980) Protective effect of immunization with heat -labile enterotoxin in gnotobiotic rats monocontaminated with enterotoxigenic *Escherichia coli*. *Inf. Immunol.*, 28, 163-170.
- LAEMMLI, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature (Lond.)* 227 : 680.
- LEONG et. al. (1985) Nucleotide sequence comparison between heat labile toxin B-subunit cistrons from *Escherichia coli* of human and porcine origin *Infection and Immunity* 48 73-77.
- 50 LEVINE, M.N., Rennels, M.B., Daya, V. & Hughes, T.P. (1980) Haemagglutination and colonization factors in enterotoxigenic and enteropathogenic *Escherichia coli* that cause diarrhea. *J. Inf. Dis.*, 141, 733-737.
- LITTLE, J.R. & Eisen, H.N. (1967) Preparation of immunogenic 2,4-dinitrophenyl and 2,4,6- trinitrophenyl proteins. In "Methods in Immunology and Immunochemistry" (Ed. Williams, C.A. & Chase, M.W.). I, p.128.
- 55 Academic Press, New York.
- MESSIER, B., and C.P. Le Blond (1960). Cell proliferation and migration as revealed by radioautography after injection of thymidine -H3 into male rats and mice. *An. J. Anat.* 106 : 247.
- MESSING (1983) New M13 V ctors for cloning *Methods in Enzymology* 101 20-78

- MORGAN, R.L., Isaacson, R.E., Moon, H.W., Brinton, C.C. & To, C.-C. (1978) Immunization of suckling pigs against enterotoxigenic *Escherichia coli*-induced diarrheal disease by vaccinating dams with purified 987 or K99 pili. *Inf. Immun.*, 22, 771-777.
- MORRIS, J.A., C.J. Thorns, and W.J. Sojka. 1980. Evidence for two adhesive antigens on the K99 reference strain *Escherichia coli* B41. *J. Gen. Microbiol.* 118 : 107.
- 5 MOWAT, A. Mcl., (1985) The role of antigen recognition and suppressor cells in mice with oral tolerance to ovalbumin. *Immun.*, 56, 253-260.
- MOWAT, A.Mcl. & PARROT, D.M.V. (1983) Immunological responses to fed protein antigens in mice. *Immun.*, 50, 547-554.
- 10 NGAN, J. & KIND, L.S. (1978) Suppressor T cells for IgE and IgG in peyer's patches of mice tolerant by the oral administration of ovalbumin. *J. Immunol.*, 120, 881-885.
- PIERCE, N.F. & KOSTER, F.T. (1980) Priming and suppression of the intestinal immune response to cholera toxoid/toxin by parenteral toxoid in rats. *J. Immunol.*, 124, 307-311.
- PIERCE, N.F., SACK, R.B., & SIRCAR, B.K., (1977) Immunity to experimental cholera. *J. Inf. Dis.*, 135, 888-896.
- 15 RICHMAN, L.K., CHILLER, J.M., BROWN, W.R., HANSON, D.G. & NELSON, N.M. (1978) Enterically induced immunological tolerance. *J. Immunol.*, 121, 2429-2434.
- RICHMAN, L.K., A.S. Graeff, and W. Strober. 1981 Antigen presentation by macrophage enriched cells from the mouse Peyer's patch. *Cell Immunol.* 62 : 1100.
- 20 ROTHBERG R.M., KRAFT, S.C., & MICHALEK, S.M., (1973) Systemic immunity after local antigenic stimulation of the lymphoid tissue of the gastrointestinal tract. *J. Immunol.*, 111, 1906-1913.
- RUSSELL-JONES, G.J., E.C. Gotschlich, and M.S. Blake. 1984. A surface receptor specific for human IgA on group B streptococci possessing the Ibc protein antigen. *J. Exp. Med.* 160 : 1467.
- RUSSELL-JONES, G.J., and E.C. Gotschlich. 1984. Identification of protein antigens of group B streptococci, with special reference to the Ibc antigen. *J. Exp. Med.* 160 1476.
- 25 SALIT, I.E., M. Blake, and E.C. Gotschlich. 1980. Intrastrain heterogeneity of gonococcal pili is related to capacity colony variance. *J. Exp. Med.* 151 : 716.
- SCHALLY AND COY (1983). Stimulatory and inhibitory analogues of LH-releasing hormone: Basic and clinical studies in Role of Peptides and Proteins in Control of Reproduction McCann and Dhindsa eds. Elsevier Science Publishing Co. Inc. pp89-110. Maniatis, Fritsch and Sambrook (1982) Molecular Cloning, Laboratory Manual. Cold Spring Harbour Laboratory.
- 30 SEVENNERHOLM, A.M. & Holmgren, J. 1978 Identification of *E. coli* heat-labile enterotoxin by means of a ganglioside immunosorbent assay (GM-1 ELISA) procedure. *Curr. Microbiol.* 1, 19-23.
- TOMASI, T.B., (1980) Oral tolerance. *Transplantation*, 29, 353.
- 35 TONER, P.G., K.E. Carr, and G.M. Wyburn (1971). Intestine. In *The Digestive System - An Ultrastructural Atlas and Review*, Butterworths, London.
- TSAI, C.M., and Frasch, C.E. 1982. A sensitive silver stain for detecting lipopolysaccharide in polyacrylamide gels. *Anal. Biochem.*, 119, 115-119. 175

40 Claims

1. A complex characterised in that it comprises an immunogen suitable for vaccination purposes linked to a carrier molecule capable of specifically binding to the epithelial mucosa of a vertebrate host, wherein both the immunological activity of the immunogen and the capacity of the carrier to bind specifically to the mucosal epithelium is substantially maintained, and the carrier molecule is an epithelial mucosal binding molecule selected from all, a part, an analogue, a homologue, a derivative or combination thereof, of a bacterial adhesin, viral haemagglutinin, a toxin, or a binding subunit of a toxin or a lectin, but not including immunogen-carrier complexes wherein the immunogen is naturally linked to the carrier molecule.
- 45 2. A complex according to claim 1, wherein said immunogen is selected from an antigen or hapten, or all, part(s), an analogue, homologue, derivative or combination thereof, of a hormone, or therapeutic agent.
3. A complex according to claim 2, wherein the immunogen is all, part, an analogue, homologue, derivative or combination thereof, of a hormone selected from FSH, HGH, LHRH or inhibin.
- 50 4. A complex according to claim 1 or 2, wherein the immunogen is an allergen.
- 55

5. A complex according to claim 4, wherein the allergen is derived from grass pollen, weed pollen, tree pollen, plant pollen, cat hair, dog hair, pig hair or other epithelia, or house dust, wheat chaff or kapok.
6. A complex according to claim 1 or 2, wherein the immunogen is a surface protein derived from an influenza, measles, Rubella, smallpox, yellow fever, diphtheria, tetanus, cholera, plague, Typhus or BCG causing agent, Haemophilus influenza, Neisseria catarrhalis, Klebsiella pneumoniae, a pneumococcus or a Streptococcus; or a pilus derived from E. coli, N. gonorrhoeae, N. meningitidis, N. catarrhalis, a Yersinia species, Pseudomonas aeruginosa, a Pseudomonas species, Moraxella bovis, Bacteroides nodosus, a Staphylococci species, a Streptococci species or a Bordetella species.
7. A complex according to claim 1 or 2, wherein the immunogen is a surface polysaccharide derived from a diphtheria, tetanus, cholera, plague, Typhus or BCG causing agent, Haemophilus influenza, Neisseria catarrhalis, Klebsiella pneumoniae, a pneumococcus or a Streptococcus.
8. A complex according to claim 1 or 2, wherein the immunogen is a secretory product derived from a diphtheria, tetanus, cholera, plague, Typhus or BCG causing agent, Haemophilus influenza, Neisseria catarrhalis, Klebsiella pneumoniae, a Pneumococcus or a Streptococcus.
9. A complex according to any one of claims 6 to 8, wherein the surface protein, surface polysaccharide or secretory product is derived from Streptococcus mutans.
10. A complex according to claim 1, wherein the carrier molecule is the heat labile toxin of enterotoxigenic E. coli.
11. A complex according to claim 1, wherein the bacterial adhesin is the K99 or 987P pilus of E. coli.
12. A complex according to claim 1, wherein the bacterial adhesin is CFAI, CFAll, K88 or F41.
13. A complex according to claim 1, wherein the lectin is Concanavalin A, Pokeweed mitogen or the lectin from Lens culinaris, Helix pomatia, Glycine max, Arachis hypogaea, or Ulex europeus.
14. A complex according to claim 1, wherein the lectin is Abrin, Asparagus pea, Broad bean, Camel's foot tree, Caster bean, Fava bean, Green marine algae, Hairy vetch, Horsegum, Horseshoe crab, Jack bean, Japanese wisteria, Jequirity bean, Scotch laburnum, Lima bean, Limulin, Lotus, European mistletoe, Mung bean, Osage orange, Pagoda tree, Garden pea, Potato, Red Kidney bean, Red marine algae, Siberian pea tree, edible snail, garden snail, Spindle tree, Sweet pea, Tomato, Wheat germ or Winged pea lectin.
15. A complex according to claim 1, wherein the viral haemagglutinin is a haemagglutinin derived from influenza, measles, Rubella, smallpox or yellow fever virus.
16. A complex according to any one of claims 1 to 3, wherein the immunogen is all, part, an analogue, homologue, derivative or combination thereof, of luteinizing hormone releasing hormone and the carrier molecule is all, part, an analogue, homologue, derivative or combination thereof, of LTB.
17. A process for the production of a complex according to any one of claims 1 to 16, which process comprises:
 - (a) reacting the immunogen with the carrier molecule to form said complex;
 - (b) chemically modifying the immunogen to provide at least one functional group capable of forming a chemical linkage, and reacting the immunogen and carrier molecule to form said complex;
 - (c) chemically modifying the carrier molecule to provide at least one functional group capable of forming a chemical linkage, and reacting the immunogen and carrier molecule to form said complex;
 - (d) chemically modifying the immunogen and the carrier molecule to provide functional groups capable of forming a chemical linkage, and reacting the immunogen and carrier molecule to form said complex;
 - (e) reacting the immunogen with at least one linking agent, and reacting the immunogen and carrier molecule to form said complex;

- (f) reacting the carrier molecule with at least one linking agent, and reacting the immunogen and carrier molecule to form said complex;
 (g) reacting the immunogen and carrier molecule with at least one linking agent, and reacting the immunogen and carrier molecule to form said complex; or
 5 (h) a combination of any of the preceding process steps.
18. A process for the production of a complex according to any one of claims 1 to 3, which process comprises:
 10 providing a recombinant DNA molecule comprising a first DNA sequence which on expression codes for the amino acid sequence of the immunogen, a second DNA sequence which on expression codes for the amino acid sequence of the carrier molecule, and vector DNA; transforming a host with the recombinant DNA molecule so that said host is capable of expressing a hybrid, proteinaceous product which comprises said complex; culturing the host to obtain expression; and collecting the hybrid proteinaceous product.
19. A process for the production of a complex according to any one of claims 1 to 16, which process comprises:
 15 (a) chemically synthesizing the immunogen and/or the carrier molecule, and forming the complex by reactions according to the process of Claim 17; or
 20 (b) synthesizing a hybrid peptide comprising amino acid sequences of the immunogen and the carrier molecule.
20. A process according to claim 19, wherein the peptide is prepared by solid phase, enzymatic or manual peptide synthesis.
21. A process according to claim 20, wherein the synthesized immunogen or carrier molecule is coupled to the carrier molecule or immunogen whilst bound to a resin of a solid phase peptide synthesizer.
22. A process according to any one of claims 19 to 21, wherein the immunogen is all, part, an analogue, homologue, derivative or combination thereof, of luteinizing hormone releasing hormone (LHRH).
23. A process according to claim 17, wherein the carrier molecule is LTB and the linking agent is isoglutaraldehyde.
24. A complex according to any one of claims 1 to 3, made by a process according to any one of claims 17 to 21.
25. An expression product of a transformant host which product comprises a complex according to any one of claims 1 to 3.
26. A host transformed with a recombinant DNA molecule comprising a first DNA sequence which on expression codes for the amino acid sequence of an immunogen suitable for vaccination purposes and a second DNA sequence which on expression codes for the amino acid sequence of a carrier molecule capable of binding to the epithelial mucosa, which carrier molecule is an epithelial mucosal binding molecule selected from all, part, an analogue, homologue, derivative or combination thereof, of a bacterial adhesin, a viral haemagglutinin, a toxin, or a binding subunit of a toxin, or a lectin, wherein the immunogen and carrier molecule form a fusion polypeptide, but not including a DNA molecule coding for an immunogen-carrier complex wherein the immunogen is naturally linked to the carrier molecule.
27. A transformant host according to claim 26, wherein the host is a Gram negative or Gram positive bacterium, a yeast, fungus, or a higher eukaryotic cell.
28. A transformant host according to claim 26 or claim 27, wherein the host is E. coli.
29. A recombinant DNA molecule comprising a DNA sequence which on expression codes for a fusion polypeptide comprising the amino acid sequence of an immunogen suitable for vaccination purposes, and the amino acid sequence of a carrier molecule capable of binding to the epithelial mucosa, which carrier molecule is an epithelial mucosal binding molecule selected from all, part, an analogue,

homologue, derivative or combination thereof, of a bacterial adhesin, a viral haemagglutinin, a toxin, or a binding subunit of a toxin, or a lectin, but not including a DNA molecule coding for an immunogen carrier complex wherein the immunogen is naturally linked to the carrier molecule.

- 5 30. A recombinant DNA molecule according to claim 29 also comprising vector DNA.
31. A recombinant DNA molecule according to claim 30, wherein the vector DNA is selected from plasmid, viral, bacteriophage, or cosmid DNA.
- 10 32. A recombinant DNA molecule according to claim 29, wherein the DNA sequence acts as a coding sequence for an antigen or hapten fused to the amino acid sequence of the carrier molecule.
33. A recombinant DNA molecule according to claim 29, wherein the DNA sequence acts as a coding sequence for all, part, an analogue, homologue, derivative of LHRH fused to the amino acid sequence of the carrier molecule.
- 15 34. A medicament which comprises an immunogen suitable for vaccination purposes linked to a carrier molecule capable of specifically binding to the epithelial mucosa of a vertebrate host, wherein both the immunological activity of the immunogen and the capacity of the carrier to bind specifically to the mucosal epithelium is substantially maintained, and the carrier molecule is an epithelial mucosal binding molecule selected from all, a part, an analogue, a homologue, a derivative or combination thereof, of a bacterial adhesin, viral haemagglutinin, a toxin, or a binding subunit of a toxin, or a lectin, together with a pharmaceutically acceptable carrier or diluent but not including immunogen-carrier complexes wherein the immunogen is naturally linked to the carrier molecule.
- 20 35. A medicament according to claim 34, adapted for oral administration.
36. A medicament according to claim 34, adapted for nasal administration.
- 30 37. A medicament according to any one of claims 34 to 36, wherein said medicament is in capsule, tablet, slow release, elixir, gel, paste or nasal spray form.
38. A medicament according to any one of claims 34 to 37, which additionally comprises a dietary molecule to selectively modulate the magnitude and/or type of immune response to the immunogen of the medicament.
- 35 39. A medicament according to claim 38, wherein the dietary molecule is selected from amino acids, vitamins, monosaccharides and oligosaccharides.
- 40 40. A medicament according to claim 38 or claim 39, wherein the dietary molecule is selected from vitamin A, vitamin B₁, vitamin B₂, vitamin B₆, vitamin B₁₂, vitamin C, vitamin D, vitamin E, fructose, lactose, mannose, melibiose, sorbitol or xylose.

Patentansprüche

- 45 1. Komplex,
dadurch gekennzeichnet,
daß er ein für Impfzwecke geeignetes Immunogen umfaßt, das an ein Trägermolekül gebunden ist, welches zur spezifischen Bindung an die epitheliale Schleimhaut eines Wirbeltierwirts geeignet ist,- 50 worin sowohl die immunologische Aktivität des Immunogens als auch die Eignung des Trägers, spezifisch an das Schleimhautepithel zu binden, im wesentlichen erhalten bleibt, und das Trägermolekül ein zur Bindung an das Schleimhautepithel geeignetes Molekül ist, ausgewählt aus dem Ganzen, einem Teil, einem Analogon, einem Homologen, einem Derivat oder einer Kombination hiervon eines bakteriellen Adhesins, eines viralen Hämagglutinins, eines Toxins oder einer Bindungsuntereinheit eines Toxins oder eines Lectins, wobei jedoch Immunogen-Trägerkomplexe ausgenommen sind, worin das Immunogen natürlicherweise an das Trägermolekül gebunden ist.

2. Komplex nach Anspruch 1, worin das Immunogen ausgewählt ist aus einem Antigen oder Hapten, oder dem Ganzen, Teil(en), einem Analogon, einem Homologen, einem Derivat oder einer Kombination hiervon eines Hormons oder eines therapeutischen Mittels.
- 5 3. Komplex nach Anspruch 2, wobei das Immunogen das Ganze, ein Teil, ein Analogon, ein Homologes, ein Derivat oder eine Kombination hiervon eines Hormons ist, ausgewählt aus FSH, HGH, LHRH oder Inhibin.
4. Komplex nach Anspruch 1 oder 2, worin das Immunogen ein Allergen ist.
- 10 5. Komplex nach Anspruch 4, worin das Allergen von Gräserpollen, Unkrautpollen, Baumpollen, Pflanzenpollen, Katzenhaar, Hundehaar, Schweinehaar oder anderen Epithelien oder Hausstaub, Weizenspreu oder Kapok stammt.
- 15 6. Komplex nach Anspruch 1 oder 2, worin das Immunogen ein Oberflächenprotein ist, welches aus einem Influenza, Masern, Rubella, Pocken, Gelbfieber, Diphtherie, Tetanus, Cholera, Pest, Typhus oder BCG verursachenden Mittel, Haemophilus influenza, Neisseria catarrhalis, Klebsiella pneumoniae, einem Pneumococcus oder einem Streptococcus stammt; oder es aus einem Pilus stammt von E. coli, N. gonorrhoeae, N. meningitidis, N. catarrhalis, einer Yersinia-Art, Pseudomonas aeruginosa, einer Pseudomonas-Art, Moraxella bovis, Bacteroides nodosus, einer Staphylokokken-Art, einer Streptokokken-Art oder einer Bordetella-Art.
- 20 7. Komplex nach Anspruch 1 oder 2, worin das Immunogen ein Oberflächenpolysaccharid ist, das aus einem Diphtherie, Tetanus, Cholera, Pest, Typhus oder BCG verursachenden Mittel, Haemophilus influenza, Neisseria catarrhalis, Klebsiella pneumoniae, einem Pneumococcus oder einem Streptococcus stammt.
- 25 8. Komplex nach Anspruch 1 oder 2, worin das Immunogen ein sekretorisches Produkt ist, das aus einem Diphtherie, Tetanus, Cholera, Pest, Typhus, oder BCG verursachenden Mittel, Haemophilus influenza, Neisseria catarrhalis, Klebsiella pneumoniae, einem Pneumococcus oder einem Streptococcus stammt.
- 30 9. Komplex nach einem der Ansprüche 6 bis 8, worin das Oberflächenprotein, das Oberflächenpolysaccharid oder das sekretorische Produkt aus Streptococcus mutans stammt.
- 35 10. Komplex nach Anspruch 1, worin das Trägermolekül ein hitzelabiles Toxin des enterotoxigenen E. coli ist.
11. Komplex nach Anspruch 1, worin das bakterielle Adhesin der K99- oder 987P-Pilus von E. coli ist.
- 40 12. Komplex nach Anspruch 1, worin das bakterielle Adhesin CFAI, CFAll, K88 oder F41 ist.
13. Komplex nach Anspruch 1, worin das Lectin Concanavalin A, Pokeweed Mitogen oder das Lectin aus Lens culinaris, Helix pomatia, Glycine max, Arachis hypogaea oder Ulex europeus ist.
- 45 14. Komplex nach Anspruch 1, worin das Lectin Abrin-, Asparagus-Erbse-, Saubohnen-, Kamelfußbaum-, Caster-Bohnen-, Fava-Bohnen-, marine Grünalgen-, haarige Wicken-, Pferdekichererbsen- (horse gram), Hufeisenkrabben-, Jack-Bohnen-, Japanische Glyzinen-, Jequirity-Bohnen-, Schottischer Goldregen-, Lima-Bohnen-, Limulin-, Lotus-, Europäische Mistel-, Mungbohnen-, Osage-Orange-, Pagodenbaum-, Gartenbohnen-, Kartoffel-, Rote Kidney-Bohnen-, marine Rotalgen-, Sibirischer Erbsenbaum-, eßbare Schnecken-, Gartenschnecken-, Spindelbaum-, süße Erbsen-, Tomaten-, Weizenkeim- oder Wingederbsen-Lectin ist.
- 50 15. Komplex nach Anspruch 1, worin das virale Hämagglutinin ein Hämagglutinin ist, das aus Influenza-, Masern-, Rubella-, Pocken- oder Gelbfiebervirus stammt.
- 55 16. Komplex nach einem der Ansprüche 1 bis 3, worin das Immunogen das Ganze, ein Teil, ein Analogon, ein Homologes, ein Derivat, oder eine Kombination hiervon des Lutinisierungshormon-freisetzenden Hormons und das Trägermolekül das Ganze, ein Teil, ein Analogon, ein Homologes, ein Derivat oder

eine Kombination hiervon von LTB ist.

17. Verfahren zur Herstellung eines Komplexes nach einem der Ansprüche 1 bis 16, wobei das Verfahren die folgenden Schritte aufweist:
 - (a) Umsetzung des Immunogens mit dem Trägermolekül, um den Komplex zu bilden;
 - (b) chemische Modifikation des Immunogens, um wenigstens eine funktionelle Gruppe bereitzustellen, die in der Lage ist, eine chemische Bindung auszubilden, und Umsetzung des Immunogens und des Trägermoleküls, um den Komplex zu bilden;
 - (c) chemische Modifikation des Trägermoleküls, um wenigstens eine funktionelle Gruppe bereitzustellen, die in der Lage ist, eine chemische Bindung auszubilden, und Umsetzung des Immunogens und des Trägermoleküls, um den Komplex auszubilden;
 - (d) chemische Modifikation des Immunogens und des Trägermoleküls, um funktionelle Gruppen bereitzustellen, die in der Lage sind, eine chemische Bindung auszubilden, und Umsetzung des Immunogens und des Trägermoleküls, um den Komplex auszubilden;
 - (e) Umsetzung des Immunogens mit wenigstens einem Bindungsmittel, und Umsetzung des Immunogens und des Trägermoleküls, um den Komplex auszubilden;
 - (f) Umsetzung des Trägermoleküls mit wenigstens einem Bindungsmittel, und Umsetzung des Immunogens und des Trägermoleküls, um den Komplex auszubilden;
 - (g) Umsetzung des Immunogens und des Trägermoleküls mit wenigstens einem Bindungsmittel, und Umsetzung des Immunogens und des Trägermoleküls, um den Komplex auszubilden; oder
 - (h) eine Kombination aus einem der oben genannten Verfahrensschritte.
18. Verfahren zur Herstellung eines Komplexes nach einem der Ansprüche 1 bis 3, wobei das Verfahren die nachfolgenden Verfahrensschritte aufweist:
 - Bereitstellen eines rekombinanten DNA-Moleküls, das eine erste DNA-Sequenz aufweist, die bei Expression für die Aminosäuresequenz des Immunogens codiert, eine zweite DNA-Sequenz, die bei Expression für die Aminosäuresequenz des Trägermoleküls codiert und eine Vektor-DNA; Transformation eines Wirts mit dem rekombinanten DNA-Molekül, so daß der Wirt in der Lage ist, ein Hybrid-Proteinprodukt zu exprimieren, das den Komplex umfaßt; Kultivierung des Wirts, um die Expression zu erhalten und Sammeln des Hybrid-Proteinprodukts.
19. Verfahren zur Herstellung eines Komplexes nach einem der Ansprüche 1 bis 16, wobei das Verfahren die nachfolgenden Verfahrensschritte aufweist:
 - (a) chemische Synthese des Immunogens und/oder des Trägermoleküls und Ausbildung des Komplexes durch Reaktionen nach dem Verfahren des Anspruchs 17; oder
 - (b) Synthese eines Hybridpeptids, das Aminosäuresequenzen des Immunogens und des Trägermoleküls aufweist.
20. Verfahren nach Anspruch 19, worin das Peptid durch Festphasen-, enzymatische oder manuelle Peptidsynthese hergestellt wird.
21. Verfahren nach Anspruch 20, worin das synthetisierte Immunogen oder Trägermolekül an das Trägermolekül oder Immunogen gekoppelt ist, während es an ein Harz eines Festphasen-Peptidsyntheseapparats gebunden ist.
22. Verfahren nach einem der Ansprüche 19 bis 21, worin das Immunogen das Ganze, ein Teil, ein Analogon, ein Homologes, ein Derivat oder eine Kombination hiervon des Luteinisierungshormon-freisetzenden Hormons (LHRH) ist.
23. Verfahren nach Anspruch 17, worin das Trägermolekül LTB und das Verbindungsmittel Isoglutaraldehyd ist.
24. Komplex nach einem der Ansprüche 1 bis 3, hergestellt durch ein Verfahren nach einem der Ansprüche 17 bis 21.
25. Expressionsprodukt in s transformierten Wirts, dessen Produkt einen Komplex nach einem der Ansprüche 1 bis 3 umfaßt.

26. Wirt, transformiert mit einem rekombinanten DNA-Molekül, das eine erste DNA-Sequenz umfaßt, die bei Expression für die Aminosäuresequenz eines für Impfzwecke geeigneten Immunogens codiert und eine zweite DNA-Sequenz, die bei Expression für die Aminosäuresequenz eines Trägermoleküls codiert, das zur Bindung an die epitheliale Schleimhaut in der Lage ist, wobei das Trägermolekül ein zur Bindung an die epitheliale Schleimhaut geeignetes Molekül ist, ausgewählt aus dem Ganzen, einem Teil, einem Analogon, einem Homologen, einem Derivat oder einer Kombination hiervon eines bakteriellen Adhesins, eines viralen Hämagglutinins, eines Toxins oder einer Bindungsuntereinheit eines Toxins, oder eines Lectins, worin das Immunogen und das Trägermolekül ein Fusionspolypeptid bilden, ausgenommen ein DNA-Molekül, das für einen Immunogen-Trägerkomplex codiert, worin das Immunogen an das Trägermolekül natürlicherweise gebunden ist.
27. Transformierter Wirt nach Anspruch 26, worin der Wirt ein Gram-negatives oder ein Gram-positives Bakterium, eine Hefe, ein Pilz oder eine höhere eukaryontische Zelle ist.
28. Transformierter Wirt nach Anspruch 26 oder 27, worin der Wirt E. coli ist.
29. Rekombinantes DNA-Molekül, das eine DNA-Sequenz aufweist, die bei Expression für ein Fusionspolypeptid codiert, das die Aminosäuresequenz eines für Impfzwecke geeigneten Immunogens umfaßt, und die Aminosäuresequenz eines zur Bindung an die epitheliale Schleimhaut geeigneten Trägermoleküls, wobei das Trägermolekül ein zur Bindung an die epitheliale Schleimhaut geeignetes Molekül ist, ausgewählt aus dem Ganzen, einem Teil, einem Analogon, einem Homologen, einem Derivat oder einer Kombination hiervon, eines bakteriellen Adhesins, eines viralen Hämagglutinins, eines Toxins oder einer Bindungsuntereinheit eines Toxins oder eines Lectins, ausgenommen ein DNA-Molekül, das für einen Immunogen-Trägerkomplex codiert, worin das Immunogen an das Trägermolekül natürlicherweise gebunden ist.
30. Rekombinantes DNA-Molekül nach Anspruch 29, das ebenfalls eine Vektor-DNA aufweist.
31. Rekombinantes DNA-Molekül nach Anspruch 30, worin die Vektor-DNA aus Plasmid-, Virus-, Bakteriophagen- oder Cosmid-DNA ausgewählt ist.
32. Rekombinantes DNA-Molekül nach Anspruch 29, worin die DNA-Sequenz als eine codierende Sequenz für ein Antigen oder ein Hapten wirkt, das mit der Aminosäuresequenz des Trägermoleküls fusioniert ist.
33. Rekombinantes DNA-Molekül nach Anspruch 29, worin die DNA-Sequenz als codierende Sequenz des Ganzen, eines Teils, eines Analogons, eines Homologen, eines Derivats von LHRH wirkt, fusioniert mit der Aminosäuresequenz des Trägermoleküls.
34. Arzneimittel, welches ein für Impfzwecke geeignetes Immunogen umfaßt, das an ein Trägermolekül gebunden ist, welches zur spezifischen Bindung an die epitheliale Schleimhaut eines Wirbeltierwirts in der Lage ist, worin sowohl die immunologische Aktivität des Immunogens als auch die Fähigkeit des Trägers, spezifisch an das Schleimhautepithel zu binden, im wesentlichen beibehalten wird, und das Trägermolekül ein zur Bindung an die epitheliale Schleimhaut geeignetes Molekül ist, ausgewählt aus dem Ganzen, einem Teil, einem Analogon, einem Homologen, einem Derivat oder einer Kombination hiervon eines bakteriellen Adhesins, eines viralen Hämagglutinins, eines Toxins oder einer Bindungsuntereinheit eines Toxins, oder eines Lectins, zusammen mit einem pharmazeutisch annehmbaren Träger oder einem Streckmittel, ausgenommen Immunogen-Trägerkomplexe, worin das Immunogen an das Trägermolekül natürlicherweise gebunden vorliegt.
35. Arzneimittel nach Anspruch 34, das zur oralen Verabreichung ausgelegt ist.
36. Arzneimittel nach Anspruch 34, das zur nasalen Administration ausgelegt ist.
37. Arzneimittel nach einem der Ansprüche 34 bis 36, worin das Arzneimittel in Kapsel-, Tabletten-, Retard-, Elixier-, Gel-, Pasten- oder Nasensprayform vorliegt.

38. Arzneimittel nach einem der Ansprüche 34 bis 37, das zusätzlich ein Nahrungsmolekül aufweist, um die Größenordnung und/oder die Art der Immunantwort auf das Immunogen des Arzneimittels selektiv zu modulieren.

5 39. Arzneimittel nach Anspruch 38, wobei das Nahrungsmolekül aus Aminosäuren, Vitaminen, Monosacchariden und Oligosacchariden ausgewählt wird.

40. Arzneimittel nach Anspruch 38 oder Anspruch 39, worin das Nahrungsmolekül ausgewählt wird aus Vitamin A, Vitamin B₁, Vitamin B₂, Vitamin B₆, Vitamin B₁₂, Vitamin C, Vitamin D, Vitamin E, Fructose, Lactose, Mannose, Melibiose, Sorbitol oder Xylose.

Revendications

15 1. Complexe caractérisé en ce qu'il comprend un immunogène vaccinal lié à une molécule porteuse capable de se fixer de manière spécifique à la muqueuse épithéliale d'un hôte vertébré, dans lequel l'activité immunologique de l'immunogène et la capacité du porteur à se fixer de manière spécifique à la muqueuse épithéliale sont toutes deux essentiellement conservées, la molécule porteuse étant une molécule capable de se fixer à la muqueuse épithéliale et choisie parmi la molécule entière, une partie, un analogue, un homologue, un dérivé ou une combinaison de ces derniers, d'une adhésine bactérienne, d'une hémagglutinine virale, d'une toxine, ou d'une sous-unité de fixation de toxine ou de lectine; complexe ne comprenant pas les complexes immunogène-porteur dans lesquels l'immunogène est lié à la molécule porteuse à l'état naturel.

25 2. Complexe selon la revendication 1, dans lequel ledit immunogène est choisi parmi un antigène ou un haptène, ou la molécule entière, une partie ou plusieurs, un analogue, un homologue, un dérivé ou une combinaison de ces derniers, d'une hormone, ou d'un agent thérapeutique.

30 3. Complexe selon la revendication 2, dans lequel l'immunogène est constitué de la molécule entière, d'une partie, d'un analogue, d'un homologue, d'un dérivé ou d'une combinaison de ces derniers, d'une hormone choisie parmi FSH, HGH, LHRH ou l'inhibine.

4. Complexe selon la revendication 1 ou 2, dans lequel l'immunogène est un allergène.

35 5. Complexe selon la revendication 4, dans lequel l'allergène est dérivé du pollen des graminées, du pollen des mauvaises herbes, du pollen des arbres, du pollen des plantes, du poil de chat, du poil de chien, du poil de porc ou autres tissus épithéliaux, ou la poussière ménagère, la balle de blé ou le kapokier.

40 6. Complexe selon la revendication 1 ou 2, dans lequel l'immunogène est une protéine de surface dérivée de l'agent étiologique de la grippe, de la rougeole, de la rubéole, de la variole, de la fièvre jaune, de la diphtérie, du tétanos, du choléra, de la peste, du typhus, ou du BCG, Haemophilus influenza, Neisseria catarrhalis, Klebsiella pneumoniae, un pneumocoque, ou un Streptocoque; ou une fimbriae dérivée d'E. coli, N. gonorrhoea, N. méningitidis, N. catarrhalis, une espèce de Yersinia, Pseudomonas aeruginosa, une espèce de Pseudomonas, Moraxella bovis, Bacteroides nodosus, une espèce de Staphylococcus, une espèce de Streptococcus ou une espèce de Bordetella.

50 7. Complexe selon la revendication 1 ou 2, dans lequel l'immunogène est un polysaccharide de surface dérivé de l'agent étiologique de la diphtérie, du tétanos, du choléra, de la peste, du typhus, ou du BCG, Haemophilus influenza, Neisseria catarrhalis, Klebsiella pneumoniae, un pneumocoque, ou un Streptocoque.

55 8. Complexe selon la revendication 1 ou 2, dans lequel l'immunogène est un produit sécrétoire dérivé de l'agent étiologique de la diphtérie, du tétanos, du choléra, de la peste, du typhus ou du BCG, Haemophilus influenza, Neisseria catarrhalis, Klebsiella pneumoniae, un pneumocoque, ou un Streptocoque.

9. Complexe selon l'une quelconque des revendications 6 à 8 dans lequel la protéine de surface, le polysaccharide de surface ou le produit sécrétoire sont dérivés de Streptococcus mutans.

10. Complexe selon la revendication 1, dans lequel la molécule porteuse est la toxine sensible à la chaleur d'une souche entérotoxigénique d'E. coli.
- 5 11. Complexe selon la revendication 1, dans lequel l'adhésine bactérienne est la fimbriae K99 ou 987P d'E. coli.
12. Complexe selon la revendication 1, dans lequel l'adhésine bactérienne est CFAI, CFAII, K88 ou F41.
- 10 13. Complexe selon la revendication 1, dans lequel la lectine est la Concanavaline A, le mitogène de Pokeweed ou la lectine obtenu à partir de Lens culinaris, Helix pomatia, Glycine max, Arachis hypogaea, ou Ulex europaeus.
14. Complexe selon la revendication 1 dans lequel la lectine est obtenue à partir de l'abrine, l'asperge, la fève, l'épine de chameau, la graine de ricin, la févérole; les algues marines vertes, la vesce commune, 15 le pois chiche, le pommier sauvage, le haricot blanc, la glycine, la liane à réglisse, le faux ébénier, le haricot de Lima, la Limuline, le lotus, le gui d'Espagne, le haricot mung, l'orange des Osages, le sophora du Japon, les petits pois, la pomme de terre, le haricot rouge, les algues marines rouges, le pois vivace de Chine, l'escargot comestible, l'escargot des champs, le fusain, le pois de senteur, la tomate, le germe de blé ou le pois à rames.
- 20 15. Complexe selon la revendication 1, dans lequel l'hémagglutinine virale est une hémagglutinine dérivée du virus de la grippe, de la rougeole, de la rubéole, de la variole ou de la fièvre jaune.
- 25 16. Complexe selon l'une quelconque des revendications 1 à 3, dans lequel l'immunogène est la molécule entière, une partie, un analogue, un homologue, un dérivé ou une combinaison de ces derniers, de la lutéostimuline et la molécule porteuse est la molécule entière, une partie, un analogue, un homologue, un dérivé ou une combinaison de ces derniers, de LTB.
- 30 17. Procédé pour la production d'un complexe selon l'une quelconque des revendications 1 à 16, lequel procédé consistant à:
 - (a) faire réagir l'immunogène avec la molécule porteuse afin de produire ledit complexe;
 - (b) modifier chimiquement l'immunogène pour générer au moins un groupe fonctionnel capable de former une liaison chimique, et à faire réagir l'immunogène et la molécule porteuse pour générer ledit complexe; ou
 - 35 (c) modifier chimiquement la molécule porteuse afin de générer au moins un groupe fonctionnel capable de former une liaison chimique, et à faire réagir l'immunogène avec la molécule porteuse afin de générer ledit complexe;
 - (d) modifier chimiquement l'immunogène et la molécule porteuse afin de générer des groupes fonctionnels capables de former une liaison chimique, et à faire réagir l'immunogène avec la 40 molécule porteuse afin de former ledit complexe;
 - (e) faire réagir l'immunogène avec au moins un agent réticulant, et à faire réagir l'immunogène avec la molécule porteuse afin de former ledit complexe;
 - (f) faire réagir la molécule porteuse avec au moins un agent réticulant et à faire réagir l'immunogène avec la molécule porteuse afin de former ledit complexe;
 - 45 (g) faire réagir l'immunogène avec la molécule porteuse en présence d'au moins un agent réticulant, et à faire réagir l'immunogène avec la molécule porteuse afin de former ledit complexe; ou à
 - (h) employer une combinaison quelconque des étapes opératoires précédentes.
- 50 18. Procédé pour la production d'un complexe selon l'une quelconque des revendications 1 à 3, lequel procédé consistant à:
 - fournir une molécule d'ADN recombinant comprenant une première séquence d'ADN qui code lors de son expression pour la séquence d'acides aminés de l'immunogène, une seconde séquence d'ADN qui code lors de son expression pour la séquence d'acides aminés de la molécule porteuse, et un vecteur d'ADN; à transformer un hôte avec ladite molécule d'ADN recombinant de sorte que ledit hôte 55 soit capable d'exprimer un produit protéique hybride qui comprend ledit complexe; à mettre en culture ledit hôte afin d'obtenir ladite expression; et à recueillir ledit produit protéique hybride.

19. Procédé pour la production d'un complexe selon l'une quelconque des revendications 1 à 16, lequel procédé consistant à
 - (a) synthétiser par voie chimique l'immunogène et/ou la molécule porteuse, et à générer le complexe au moyen des réactions du procédé selon la revendication 17; ou à
 - (b) synthétiser un peptide hybride comportant la séquence d'acides aminés de l'immunogène et celle de la molécule porteuse.
20. Procédé selon la revendication 19, dans lequel on prépare le peptide par synthèse peptidique enzymatique, manuelle ou sur phase solide.
21. Procédé selon la revendication 20, dans lequel on couple l'immunogène synthétisé ou la molécule porteuse après fixation sur la résine de la phase solide du synthétiseur peptidique à la molécule porteuse ou à l'immunogène respectivement.
22. Procédé selon l'une quelconque des revendications 19 à 21, dans lequel l'immunogène est la molécule entière, une partie, un analogue, un homologue, un dérivé ou une combinaison de ces derniers, de la lutéostimuline (LHRH).
23. Procédé selon la revendication 17, dans lequel la molécule porteuse est LTB et l'agent réticulant est l'isoglutaraldéhyde.
24. Complexe selon l'une quelconque des revendications 1 à 3, fabriqué par un procédé selon l'une quelconque des revendications 17 à 21.
25. Produit d'expression d'un hôte transformé; lequel produit comprenant un complexe selon l'une quelconque des revendications 1 à 3.
26. Hôte transformé avec une molécule d'ADN recombinant comportant une première séquence d'ADN qui lors de son expression code pour les séquences d'acides aminés d'un immunogène vaccinal et une seconde séquence d'ADN qui lors de son expression code pour la séquence d'acides aminés d'une molécule porteuse capable de se lier à la muqueuse épithéliale, laquelle molécule porteuse étant une molécule capable de se lier à la muqueuse épithéliale et choisie parmi la molécule entière, une partie, un analogue, un homologue, un dérivé ou une combinaison de ces derniers, d'une adhésine bactérienne, d'une hémagglutinine virale, d'une toxine, ou d'une sous-unité de fixation d'une toxine, ou d'une lectine, hôte dans lequel l'immunogène et la molécule porteuse génèrent un polypeptide de fusion; molécule ne comprenant pas une molécule d'ADN codant pour un complexe immunogène-porteur dans lequel l'immunogène est lié à la molécule porteuse à l'état naturel.
27. Hôte transformé selon la revendication 26, dans lequel l'hôte est une bactérie Gram négative, Gram positive, une levure, une moisissure, ou une cellule eucaryote supérieure.
28. Hôte transformé selon la revendication 26 ou la revendication 27, dans lequel l'hôte est E. coli.
29. Molécule d'ADN recombinant comprenant une séquence d'ADN qui lors de son expression code pour un polypeptide de fusion qui comporte la séquence d'acides aminés d'un immunogène vaccinal, et la séquence d'acides aminés d'une molécule porteuse capable de se lier à la muqueuse épithéliale, laquelle molécule porteuse étant une molécule capable de se fixer à la muqueuse épithéliale et choisie parmi la molécule entière, une partie, un analogue, un homologue, un dérivé ou une combinaison de ces derniers, d'une adhésine bactérienne, d'une hémagglutinine virale, d'une toxine, ou d'une sous-unité de liaison d'une toxine, ou d'une lectine, molécule ne comprenant pas une molécule d'ADN codant pour un complexe immunogène-porteur dans lequel l'immunogène est lié à la molécule porteuse à l'état naturel.
30. Molécule d'ADN recombinant selon la revendication 29 comprenant en outre un vecteur d'ADN.
31. Molécule d'ADN recombinant selon la revendication 30, dans laquelle le vecteur d'ADN est choisi parmi un ADN plasmidique, viral, de bactériophage ou de cosmide.

32. Molécule d'ADN recombinant selon la revendication 29, dans laquelle la séquence d'ADN agit comme une séquence codant pour un antigène ou haptène fusionné à la séquence d'acides aminés de la molécule porteuse.
- 5 33. Molécule d'ADN recombinant selon la revendication 29, dans laquelle la séquence d'ADN agit comme une séquence codant pour la molécule entière, une partie, un analogue, un homologue, un dérivé de LHRH fusionné à la séquence d'acides aminés de la molécule porteuse.
- 10 34. Médicament qui comprend un immunogène vaccinal lié à une molécule porteuse capable de se lier spécifiquement à la muqueuse épithéliale d'un hôte vertébré, dans lequel l'activité immunologique de l'immunogène et la capacité du porteur à se fixer de manière spécifique à la muqueuse épithéliale sont toutes deux essentiellement conservées, la molécule porteuse étant une molécule capable de se fixer à la muqueuse épithéliale et choisie parmi la molécule entière, une partie, un analogue, un homologue, un dérivé ou une combinaison de ces derniers, d'une adhésine bactérienne, d'une hémagglutinine
15 virale, d'une toxine, ou d'une sous-unité de fixation d'une toxine ou d'une lectine, en association avec un véhicule ou un diluant pharmaceutiquement acceptable, médicament ne comprenant pas les complexes immunogène-porteur dans lesquels l'immunogène est lié à la molécule porteuse à l'état naturel.
- 20 35. Médicament selon la revendication 34, approprié à l'administration orale.
36. Médicament selon la revendication 34, approprié à l'administration nasale.
- 25 37. Médicament selon l'une quelconque des revendications 34 à 36, dans lequel ledit médicament est sous forme de capsule, de comprimé, de médicament à libération lente, d'éllixir, de gel, de pâte, ou de spray nasal.
- 30 38. Médicament selon l'une quelconque des revendications 34 à 37, qui comprend en outre une molécule diététique destinée à moduler de manière sélective l'intensité et/ou le type de réponse immune vis-à-vis de l'immunogène présent dans le médicament.
39. Médicament selon la revendication 38, dans lequel la molécule diététique est choisie parmi les acides aminés, les vitamines, les monosaccharides et les oligosaccharides.
- 35 40. Médicament selon la revendication 38 ou la revendication 39, dans lequel la molécule diététique est choisie parmi la vitamine A, la vitamine B₁, la vitamine B₂, la vitamine B₆, la vitamine B₁₂, la vitamine C, la vitamine D, la vitamine E, le fructose, le lactose, le mannose, le mélibiose, le sorbitol ou le xylosé.

40

45

50

55

	1	5	10
Type 1	Ala-Ala-Thr-Thr-Val-Asn-Gly-Gly-Thr-Val-His-Phe-Lys-Gly-		
K88	Trp-Met-Thr-Gly-Asp-Phe-Asn-Gly-Ser-Val-Asp-Ile-Gly-Gly-		
K99	Asn-Thr-Gly-Thr-Ile-Asn-Phe-Asn-Gly-Lys-Ile-Thr-Ser-Ala-		
987P	Ala-Pro-Val-Glu-Asn-Asn-Thr-Cys-Gln-Ala-Asn-Leu-Asp-Phe-		
Neisseria	Phe-Thr-Leu-Ile-Glu-Leu-Met-Ile-Val-Ile-Ala-Ile-Val-Gly-		
	15	20	25
Type 1	Glu-Val-Val-Asn-Ala-Ala-		
K88	Ser-Ile-Thr-Ala-Asp-Asp-Tyr-Arg-		
K99	Thr-Cys-Thr-Ile-Glu-Pro-Glu-Ala-		
987P	Thr-Gly-Lys-Val-Thr-Ala- x -Leu-		
Neisseria	Ile-Leu-Ala-Ala-Val-Ala-Leu-Pro-		

Fig.1 N-terminal amino acid sequence of the 987P pilin subunit. The N-terminal sequences of other pilin proteins are given for comparison.